{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T22:07:21Z","timestamp":1785190041176,"version":"3.55.0"},"reference-count":339,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2023,9,12]],"date-time":"2023-09-12T00:00:00Z","timestamp":1694476800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,9,12]],"date-time":"2023-09-12T00:00:00Z","timestamp":1694476800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Neurobiol"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1007\/s12035-023-03604-4","type":"journal-article","created":{"date-parts":[[2023,9,12]],"date-time":"2023-09-12T08:02:27Z","timestamp":1694505747000},"page":"1237-1270","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["A clinical study and future prospects for bioactive compounds and semi-synthetic molecules in the therapies for Huntington's disease"],"prefix":"10.1007","volume":"61","author":[{"given":"Md. Rezaul","family":"Islam","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maruf Hossain","family":"Jony","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gazi Kaifeara","family":"Thufa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shopnil","family":"Akash","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Puja Sutra","family":"Dhar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Md. Mominur","family":"Rahman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tahmina","family":"Afroz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muniruddin","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hassan A.","family":"Hemeg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdur","family":"Rauf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muthu","family":"Thiruvengadam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3888-7079","authenticated-orcid":false,"given":"Baskar","family":"Venkidasamy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,9,12]]},"reference":[{"key":"3604_CR1","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/J.BIOCEL.2010.10.014","volume":"43","author":"S Krobitsch","year":"2011","unstructured":"Krobitsch S, Kazantsev AG (2011) Huntington\u2019s disease: from molecular basis to therapeutic advances. Int J Biochem Cell Biol 43:20\u201324. https:\/\/doi.org\/10.1016\/J.BIOCEL.2010.10.014","journal-title":"Int J Biochem Cell Biol"},{"key":"3604_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S1734-1140(10)70238-3","volume":"62","author":"P Kumar","year":"2010","unstructured":"Kumar P, Kalonia H, Kumar A (2010) Huntington\u2019s disease: pathogenesis to animal models. Pharmacol Rep 62:1\u201314. https:\/\/doi.org\/10.1016\/S1734-1140(10)70238-3","journal-title":"Pharmacol Rep"},{"key":"3604_CR3","doi-asserted-by":"publisher","unstructured":"Ross CA, Aylward EH, Wild EJ, Langbehn DR, Long JD, Warner JH, Scahill RI, Leavitt BR et al (2014) Huntington disease: natural history, biomarkers and prospects for therapeutics. Nat Rev Neurol 10(4):204\u201316. https:\/\/doi.org\/10.1038\/nrneurol.2014.24","DOI":"10.1038\/nrneurol.2014.24"},{"key":"3604_CR4","doi-asserted-by":"publisher","first-page":"2803","DOI":"10.1111\/J.1460-9568.2008.06310.X","volume":"27","author":"JM Gil","year":"2008","unstructured":"Gil JM, Rego AC (2008) Mechanisms of neurodegeneration in Huntington\u2019s disease. Eur J Neurosci 27:2803\u20132820. https:\/\/doi.org\/10.1111\/J.1460-9568.2008.06310.X","journal-title":"Eur J Neurosci"},{"key":"3604_CR5","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1080\/14737175.2019.1631161","volume":"19","author":"H Bashir","year":"2019","unstructured":"Bashir H (2019) Emerging therapies in Huntington\u2019s disease. Expert Rev Neurother 19:983\u2013995. https:\/\/doi.org\/10.1080\/14737175.2019.1631161","journal-title":"Expert Rev Neurother"},{"key":"3604_CR6","doi-asserted-by":"publisher","unstructured":"Bates GP, Dorsey R, Gusella JF, Hayden MR, Kay C, Leavitt BR, Nance M, Ross CA et al (2015) Huntington disease. Nat Rev Dis Primers 1:15005. https:\/\/doi.org\/10.1038\/nrdp.2015.5","DOI":"10.1038\/nrdp.2015.5"},{"key":"3604_CR7","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1021\/ACSCHEMNEURO.0C00824","volume":"12","author":"PT Lum","year":"2021","unstructured":"Lum PT, Sekar M, Gan SH et al (2021) Protective effect of natural products against Huntington\u2019s disease: an overview of scientific evidence and understanding Their Mechanism of Action. ACS Chem Neurosci 12:391\u2013418. https:\/\/doi.org\/10.1021\/ACSCHEMNEURO.0C00824","journal-title":"ACS Chem Neurosci"},{"key":"3604_CR8","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1016\/J.JTCME.2020.03.008","volume":"10","author":"HF Chiu","year":"2020","unstructured":"Chiu HF, Venkatakrishnan K, Wang CK (2020) The role of nutraceuticals as a complementary therapy against various neurodegenerative diseases: a mini-review. J Tradit Complement Med 10:434\u2013439. https:\/\/doi.org\/10.1016\/J.JTCME.2020.03.008","journal-title":"J Tradit Complement Med"},{"key":"3604_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.7916\/TOHM.V0.678","volume":"9","author":"M Yu","year":"2019","unstructured":"Yu M, Bega D (2019) A Review of the clinical evidence for complementary and alternative medicine in Huntington\u2019s disease. Tremor Other Hyperkinet Mov (N Y) 9:1\u20139. https:\/\/doi.org\/10.7916\/TOHM.V0.678","journal-title":"Tremor Other Hyperkinet Mov (N Y)"},{"key":"3604_CR10","doi-asserted-by":"publisher","first-page":"105047","DOI":"10.1016\/J.JFF.2022.105047","volume":"92","author":"P Singh","year":"2022","unstructured":"Singh P, Mishra G, Molla M et al (2022) Dietary and nutraceutical-based therapeutic approaches to combat the pathogenesis of Huntington\u2019s disease. J Funct Foods 92:105047. https:\/\/doi.org\/10.1016\/J.JFF.2022.105047","journal-title":"J Funct Foods"},{"key":"3604_CR11","doi-asserted-by":"publisher","first-page":"1156","DOI":"10.1136\/JNNP-2012-304636","volume":"84","author":"SJW Evans","year":"2013","unstructured":"Evans SJW, Douglas I, Rawlins MD et al (2013) Prevalence of adult Huntington\u2019s disease in the UK based on diagnoses recorded in general practice records. J Neurol Neurosurg Psychiatry 84:1156\u20131160. https:\/\/doi.org\/10.1136\/JNNP-2012-304636","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"3604_CR12","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1111\/J.1399-0004.2010.01538.X","volume":"80","author":"P Morrison","year":"2011","unstructured":"Morrison P, Harding-Lester S, Bradley A (2011) Uptake of Huntington disease predictive testing in a complete population. Clin Genet 80:281\u2013286. https:\/\/doi.org\/10.1111\/J.1399-0004.2010.01538.X","journal-title":"Clin Genet"},{"key":"3604_CR13","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1002\/MDS.25717","volume":"29","author":"ER Fisher","year":"2014","unstructured":"Fisher ER, Hayden MR (2014) Multisource ascertainment of Huntington disease in Canada: prevalence and population at risk. Mov Disord 29:105\u2013114. https:\/\/doi.org\/10.1002\/MDS.25717","journal-title":"Mov Disord"},{"key":"3604_CR14","doi-asserted-by":"publisher","unstructured":"Wexler NS, Lorimer J, Porter J, Gomez F, Moskowitz C, Shackell E, Marder K, Penchaszadeh G et al (2004) Venezuelan kindreds reveal that genetic and environmental factors modulate Huntington\u2019s disease age of onset. Proc Natl Acad Sci U S A 101:3498\u20133503. https:\/\/doi.org\/10.1073\/PNAS.0308679101","DOI":"10.1073\/PNAS.0308679101"},{"key":"3604_CR15","doi-asserted-by":"publisher","first-page":"2103","DOI":"10.1093\/HMG\/3.12.2103","volume":"3","author":"F Squitieri","year":"1994","unstructured":"Squitieri F, Andrew SE, Goldberg YP et al (1994) DNA haplotype analysis of Huntington disease reveals clues to the origins and mechanisms of CAG expansion and reasons for geographic variations of prevalence. Hum Mol Genet 3:2103\u20132114. https:\/\/doi.org\/10.1093\/HMG\/3.12.2103","journal-title":"Hum Mol Genet"},{"key":"3604_CR16","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1016\/J.AJHG.2009.02.003","volume":"84","author":"SC Warby","year":"2009","unstructured":"Warby SC, Montpetit A, Hayden AR et al (2009) CAG expansion in the Huntington disease gene is associated with a specific and targetable predisposing haplogroup. Am J Hum Genet 84:351\u2013366. https:\/\/doi.org\/10.1016\/J.AJHG.2009.02.003","journal-title":"Am J Hum Genet"},{"key":"3604_CR17","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.1038\/EJHG.2013.2","volume":"21","author":"FK Baine","year":"2013","unstructured":"Baine FK, Kay C, Ketelaar ME et al (2013) Huntington disease in the South African population occurs on diverse and ethnically distinct genetic haplotypes. Eur J Hum Genet 21:1120\u20131127. https:\/\/doi.org\/10.1038\/EJHG.2013.2","journal-title":"Eur J Hum Genet"},{"key":"3604_CR18","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1038\/EJHG.2010.229","volume":"19","author":"SC Warby","year":"2011","unstructured":"Warby SC, Visscher H, Collins JA et al (2011) HTT haplotypes contribute to differences in Huntington disease prevalence between Europe and East Asia. Eur J Hum Genet 19:561\u2013566. https:\/\/doi.org\/10.1038\/EJHG.2010.229","journal-title":"Eur J Hum Genet"},{"key":"3604_CR19","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1212\/WNL.0000000000002858","volume":"87","author":"C Kay","year":"2016","unstructured":"Kay C, Collins JA, Miedzybrodzka Z et al (2016) Huntington disease reduced penetrance alleles occur at high frequency in the general population. Neurology 87:282\u2013288. https:\/\/doi.org\/10.1212\/WNL.0000000000002858","journal-title":"Neurology"},{"key":"3604_CR20","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1136\/BMJ.C3109","volume":"340","author":"MJU Novak","year":"2010","unstructured":"Novak MJU, Tabrizi SJ (2010) Huntington\u2019s disease. BMJ 340:34\u201340. https:\/\/doi.org\/10.1136\/BMJ.C3109","journal-title":"BMJ"},{"key":"3604_CR21","doi-asserted-by":"publisher","unstructured":"Roos RAC (2010) Huntington\u2019s disease: a clinical review. Orphanet J Rare Dis 5. https:\/\/doi.org\/10.1186\/1750-1172-5-40","DOI":"10.1186\/1750-1172-5-40"},{"key":"3604_CR22","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/J.NEURO.2017.01.005","volume":"61","author":"TK Chao","year":"2017","unstructured":"Chao TK, Hu J, Pringsheim T (2017) Risk factors for the onset and progression of Huntington disease. Neurotoxicology 61:79\u201399. https:\/\/doi.org\/10.1016\/J.NEURO.2017.01.005","journal-title":"Neurotoxicology"},{"issue":"42","key":"3604_CR23","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1007\/S10863-010-9288-5","volume":"423","author":"M Pandey","year":"2010","unstructured":"Pandey M, Mohanakumar KP (2010) Usha R (2010) Mitochondrial functional alterations in relation to pathophysiology of Huntington\u2019s disease. J Bioenerg Biomembr 423(42):217\u2013226. https:\/\/doi.org\/10.1007\/S10863-010-9288-5","journal-title":"J Bioenerg Biomembr"},{"key":"3604_CR24","doi-asserted-by":"publisher","first-page":"4604","DOI":"10.1073\/PNAS.96.8.4604","volume":"96","author":"E Scherzinger","year":"1999","unstructured":"Scherzinger E, Sittler A, Schweiger K et al (1999) Self-assembly of polyglutamine-containing huntingtin fragments into amyloid-like fibrils: implications for Huntington\u2019s disease pathology. Proc Natl Acad Sci U S A 96:4604\u20134609. https:\/\/doi.org\/10.1073\/PNAS.96.8.4604","journal-title":"Proc Natl Acad Sci U S A"},{"key":"3604_CR25","doi-asserted-by":"publisher","unstructured":"Budworth H, Harris FR, Williams P, Lee DY, Holt A, Pahnke J, Szczesny B, Acevedo-Torres et al (2015) Suppression of somatic expansion delays the onset of pathophysiology in a mouse model of Huntington\u2019s disease. PLOS Genetics 11:e1005267. https:\/\/doi.org\/10.1371\/journal.pgen.1005267","DOI":"10.1371\/journal.pgen.1005267"},{"key":"3604_CR26","doi-asserted-by":"publisher","first-page":"3359","DOI":"10.1093\/HMG\/DDG352","volume":"12","author":"L Kennedy","year":"2003","unstructured":"Kennedy L, Evans E, Chen CM et al (2003) Dramatic tissue-specific mutation length increases are an early molecular event in Huntington disease pathogenesis. Hum Mol Genet 12:3359\u20133367. https:\/\/doi.org\/10.1093\/HMG\/DDG352","journal-title":"Hum Mol Genet"},{"key":"3604_CR27","doi-asserted-by":"publisher","first-page":"3467","DOI":"10.1073\/PNAS.0800048105","volume":"105","author":"R Gonitel","year":"2008","unstructured":"Gonitel R, Moffitt H, Sathasivam K et al (2008) DNA instability in postmitotic neurons. Proc Natl Acad Sci U S A 105:3467\u20133472. https:\/\/doi.org\/10.1073\/PNAS.0800048105","journal-title":"Proc Natl Acad Sci U S A"},{"key":"3604_CR28","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1038\/70598","volume":"23","author":"K Manley","year":"1999","unstructured":"Manley K, Shirley TL, Flaherty L, Messer A (1999) Msh2 deficiency prevents in vivo somatic instability of the CAG repeat in Huntington disease transgenic mice. Nat Genet 23:471\u2013473. https:\/\/doi.org\/10.1038\/70598","journal-title":"Nat Genet"},{"key":"3604_CR29","doi-asserted-by":"publisher","unstructured":"Tom\u00e9 S, Manley K, Simard JP et al (2013) MSH3 polymorphisms and protein levels affect CAG repeat instability in Huntington\u2019s disease mice. PLoS Genet 9. https:\/\/doi.org\/10.1371\/JOURNAL.PGEN.1003280","DOI":"10.1371\/JOURNAL.PGEN.1003280"},{"key":"3604_CR30","doi-asserted-by":"publisher","unstructured":"Pinto RM, Dragileva E, Kirby A et al (2013) Mismatch repair genes Mlh1 and Mlh3 modify CAG instability in Huntington\u2019s disease mice: genome-wide and candidate approaches. PLoS Genet 9. https:\/\/doi.org\/10.1371\/JOURNAL.PGEN.1003930","DOI":"10.1371\/JOURNAL.PGEN.1003930"},{"key":"3604_CR31","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1093\/HMG\/DDG056","volume":"12","author":"VC Wheeler","year":"2003","unstructured":"Wheeler VC, Lebel LA, Vrbanac V et al (2003) Mismatch repair gene Msh2 modifies the timing of early disease in Hdh(Q111) striatum. Hum Mol Genet 12:273\u2013281. https:\/\/doi.org\/10.1093\/HMG\/DDG056","journal-title":"Hum Mol Genet"},{"key":"3604_CR32","doi-asserted-by":"publisher","unstructured":"Moffitt H, McPhail GD, Woodman B et al (2009) Formation of polyglutamine inclusions in a wide range of non-CNS tissues in the HdhQ150 knock-in mouse model of Huntington\u2019s disease. PLoS One 4. https:\/\/doi.org\/10.1371\/JOURNAL.PONE.0008025","DOI":"10.1371\/JOURNAL.PONE.0008025"},{"key":"3604_CR33","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1038\/NRN2786","volume":"11","author":"B Frost","year":"2010","unstructured":"Frost B, Diamond MI (2010) Prion-like mechanisms in neurodegenerative diseases. Nat Rev Neurosci 11:155\u2013159. https:\/\/doi.org\/10.1038\/NRN2786","journal-title":"Nat Rev Neurosci"},{"key":"3604_CR34","doi-asserted-by":"publisher","first-page":"1064","DOI":"10.1038\/NN.3761","volume":"17","author":"E Pecho-Vrieseling","year":"2014","unstructured":"Pecho-Vrieseling E, Rieker C, Fuchs S et al (2014) Transneuronal propagation of mutant huntingtin contributes to non-cell autonomous pathology in neurons. Nat Neurosci 17:1064\u20131072. https:\/\/doi.org\/10.1038\/NN.3761","journal-title":"Nat Neurosci"},{"key":"3604_CR35","doi-asserted-by":"publisher","first-page":"11404","DOI":"10.1073\/PNAS.96.20.11404","volume":"96","author":"A Kazantsev","year":"1999","unstructured":"Kazantsev A, Preisinger E, Dranovsky A et al (1999) Insoluble detergent-resistant aggregates form between pathological and nonpathological lengths of polyglutamine in mammalian cells. Proc Natl Acad Sci U S A 96:11404\u201311409. https:\/\/doi.org\/10.1073\/PNAS.96.20.11404","journal-title":"Proc Natl Acad Sci U S A"},{"key":"3604_CR36","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1126\/SCIENCE.1141448","volume":"319","author":"WE Balch","year":"2008","unstructured":"Balch WE, Morimoto RI, Dillin A, Kelly JW (2008) Adapting proteostasis for disease intervention. Science 319:916\u2013919. https:\/\/doi.org\/10.1126\/SCIENCE.1141448","journal-title":"Science"},{"key":"3604_CR37","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1016\/J.TIBS.2013.05.003","volume":"38","author":"J Labbadia","year":"2013","unstructured":"Labbadia J, Morimoto RI (2013) Huntington\u2019s disease: underlying molecular mechanisms and emerging concepts. Trends Biochem Sci 38:378\u2013385. https:\/\/doi.org\/10.1016\/J.TIBS.2013.05.003","journal-title":"Trends Biochem Sci"},{"key":"3604_CR38","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/J.TINS.2014.09.003","volume":"38","author":"DDO Martin","year":"2015","unstructured":"Martin DDO, Ladha S, Ehrnhoefer DE, Hayden MR (2015) Autophagy in Huntington disease and huntingtin in autophagy. Trends Neurosci 38:26\u201335. https:\/\/doi.org\/10.1016\/J.TINS.2014.09.003","journal-title":"Trends Neurosci"},{"key":"3604_CR39","doi-asserted-by":"publisher","first-page":"3306","DOI":"10.1172\/JCI57413","volume":"121","author":"J Labbadia","year":"2011","unstructured":"Labbadia J, Cunliffe H, Weiss A et al (2011) Altered chromatin architecture underlies progressive impairment of the heat shock response in mouse models of Huntington disease. J Clin Invest 121:3306\u20133319. https:\/\/doi.org\/10.1172\/JCI57413","journal-title":"J Clin Invest"},{"key":"3604_CR40","doi-asserted-by":"publisher","first-page":"4906","DOI":"10.1073\/PNAS.0811228106\/SUPPL_FILE\/0811228106SI.PDF","volume":"106","author":"DA Simmons","year":"2009","unstructured":"Simmons DA, Rex CS, Palmer L et al (2009) Up-regulating BDNF with an ampakine rescues synaptic plasticity and memory in Huntington\u2019s disease knockin mice. Proc Natl Acad Sci U S A 106:4906\u20134911. https:\/\/doi.org\/10.1073\/PNAS.0811228106\/SUPPL_FILE\/0811228106SI.PDF","journal-title":"Proc Natl Acad Sci U S A"},{"key":"3604_CR41","doi-asserted-by":"publisher","first-page":"1432","DOI":"10.3390\/BIOMEDICINES10061432","volume":"10","author":"A Burillo","year":"2022","unstructured":"Burillo A, Jurcau A (2022) Molecular pathophysiological mechanisms in Huntington\u2019s disease. Biomedicines 10:1432. https:\/\/doi.org\/10.3390\/BIOMEDICINES10061432","journal-title":"Biomedicines"},{"key":"3604_CR42","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/J.BBADIS.2011.10.016","volume":"1822","author":"PH Reddy","year":"2012","unstructured":"Reddy PH, Shirendeb UP (2012) Mutant huntingtin, abnormal mitochondrial dynamics, defective axonal transport of mitochondria, and selective synaptic degeneration in Huntington\u2019s disease. Biochim Biophys Acta 1822:101\u2013110. https:\/\/doi.org\/10.1016\/J.BBADIS.2011.10.016","journal-title":"Biochim Biophys Acta"},{"key":"3604_CR43","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2174\/156652411794474419","volume":"11","author":"R Vidal","year":"2011","unstructured":"Vidal R, Caballero B, Couve A, Hetz C (2011) Converging pathways in the occurrence of endoplasmic reticulum (ER) stress in Huntington\u2019s disease. Curr Mol Med 11:1\u201312. https:\/\/doi.org\/10.2174\/156652411794474419","journal-title":"Curr Mol Med"},{"key":"3604_CR44","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1523\/JNEUROSCI.19-03-00964.1999","volume":"19","author":"M Kim","year":"1999","unstructured":"Kim M, Lee HS, LaForet G et al (1999) Mutant huntingtin expression in clonal striatal cells: dissociation of inclusion formation and neuronal survival by caspase inhibition. J Neurosci 19:964\u2013973. https:\/\/doi.org\/10.1523\/JNEUROSCI.19-03-00964.1999","journal-title":"J Neurosci"},{"key":"3604_CR45","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/J.FREERADBIOMED.2013.04.016","volume":"62","author":"A Johri","year":"2013","unstructured":"Johri A, Chandra A, Beal MF (2013) PGC-1\u03b1, mitochondrial dysfunction, and Huntington\u2019s disease. Free Radic Biol Med 62:37\u201346. https:\/\/doi.org\/10.1016\/J.FREERADBIOMED.2013.04.016","journal-title":"Free Radic Biol Med"},{"key":"3604_CR46","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/J.NEUROSCIENCE.2012.05.043","volume":"251","author":"J Nithianantharajah","year":"2013","unstructured":"Nithianantharajah J, Hannan AJ (2013) Dysregulation of synaptic proteins, dendritic spine abnormalities and pathological plasticity of synapses as experience-dependent mediators of cognitive and psychiatric symptoms in Huntington\u2019s disease. Neuroscience 251:66\u201374. https:\/\/doi.org\/10.1016\/J.NEUROSCIENCE.2012.05.043","journal-title":"Neuroscience"},{"key":"3604_CR47","doi-asserted-by":"publisher","unstructured":"Ellrichmann G, Reick C, Saft C, Linker RA (2013) The role of the immune system in Huntington\u2019s disease. Clin Dev Immunol 2013. https:\/\/doi.org\/10.1155\/2013\/541259","DOI":"10.1155\/2013\/541259"},{"key":"3604_CR48","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1038\/nm.3514","volume":"20","author":"N Wang","year":"2014","unstructured":"Wang N, Gray M, Lu XH et al (2014) Neuronal targets for reducing mutant huntingtin expression to ameliorate disease in a mouse model of Huntington\u2019s disease. Nat Med 20:536\u2013541. https:\/\/doi.org\/10.1038\/nm.3514","journal-title":"Nat Med"},{"key":"3604_CR49","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/J.MOLCEL.2004.06.029","volume":"15","author":"G Schaffar","year":"2004","unstructured":"Schaffar G, Breuer P, Boteva R et al (2004) Cellular toxicity of polyglutamine expansion proteins: mechanism of transcription factor deactivation. Mol Cell 15:95\u2013105. https:\/\/doi.org\/10.1016\/J.MOLCEL.2004.06.029","journal-title":"Mol Cell"},{"key":"3604_CR50","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1093\/HMG\/10.10.1049","volume":"10","author":"NR Jana","year":"2001","unstructured":"Jana NR, Zemskov EA, Wang GH, Nukina N (2001) Altered proteasomal function due to the expression of polyglutamine-expanded truncated N-terminal huntingtin induces apoptosis by caspase activation through mitochondrial cytochrome c release. Hum Mol Genet 10:1049\u20131059. https:\/\/doi.org\/10.1093\/HMG\/10.10.1049","journal-title":"Hum Mol Genet"},{"key":"3604_CR51","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1038\/NATURE06022","volume":"448","author":"EJ Bennett","year":"2007","unstructured":"Bennett EJ, Shaler TA, Woodman B et al (2007) Global changes to the ubiquitin system in Huntington\u2019s disease. Nature 448:704\u2013708. https:\/\/doi.org\/10.1038\/NATURE06022","journal-title":"Nature"},{"key":"3604_CR52","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1001\/ARCHNEUR.62.1.46","volume":"62","author":"S Gunawardena","year":"2005","unstructured":"Gunawardena S, Goldstein LSB (2005) Polyglutamine diseases and transport problems: deadly traffic jams on neuronal highways. Arch Neurol 62:46\u201351. https:\/\/doi.org\/10.1001\/ARCHNEUR.62.1.46","journal-title":"Arch Neurol"},{"key":"3604_CR53","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1006\/MCNE.2002.1152","volume":"20","author":"JC Li\u00e9vens","year":"2002","unstructured":"Li\u00e9vens JC, Woodman B, Mahal A, Bates GP (2002) Abnormal phosphorylation of synapsin I predicts a neuronal transmission impairment in the R6\/2 Huntington\u2019s disease transgenic mice. Mol Cell Neurosci 20:638\u2013648. https:\/\/doi.org\/10.1006\/MCNE.2002.1152","journal-title":"Mol Cell Neurosci"},{"key":"3604_CR54","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1016\/J.MOLMED.2003.08.006","volume":"9","author":"JY Li","year":"2003","unstructured":"Li JY, Plomann M, Brundin P (2003) Huntington\u2019s disease: a synaptopathy? Trends Mol Med 9:414\u2013420. https:\/\/doi.org\/10.1016\/J.MOLMED.2003.08.006","journal-title":"Trends Mol Med"},{"key":"3604_CR55","doi-asserted-by":"publisher","first-page":"24713","DOI":"10.1074\/JBC.M103501200","volume":"276","author":"Y Sun","year":"2001","unstructured":"Sun Y, Savanenin A, Reddy PH, Liu YF (2001) Polyglutamine-expanded huntingtin promotes sensitization of N-methyl-D-aspartate receptors via post-synaptic density 95. J Biol Chem 276:24713\u201324718. https:\/\/doi.org\/10.1074\/JBC.M103501200","journal-title":"J Biol Chem"},{"key":"3604_CR56","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1016\/J.NBD.2004.07.002","volume":"17","author":"S Almeida","year":"2004","unstructured":"Almeida S, Domingues A, Rodrigues L et al (2004) FK506 prevents mitochondrial-dependent apoptotic cell death induced by 3-nitropropionic acid in rat primary cortical cultures. Neurobiol Dis 17:435\u2013444. https:\/\/doi.org\/10.1016\/J.NBD.2004.07.002","journal-title":"Neurobiol Dis"},{"key":"3604_CR57","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1093\/HMG\/DDH162","volume":"13","author":"YS Choo","year":"2004","unstructured":"Choo YS, Johnson GVW, MacDonald M et al (2004) Mutant huntingtin directly increases susceptibility of mitochondria to the calcium-induced permeability transition and cytochrome c release. Hum Mol Genet 13:1407\u20131420. https:\/\/doi.org\/10.1093\/HMG\/DDH162","journal-title":"Hum Mol Genet"},{"key":"3604_CR58","doi-asserted-by":"publisher","first-page":"29427","DOI":"10.1074\/JBC.M109.013193","volume":"284","author":"CT Aiken","year":"2009","unstructured":"Aiken CT, Steffan JS, Guerrero CM et al (2009) Phosphorylation of threonine 3: implications for Huntingtin aggregation and neurotoxicity. J Biol Chem 284:29427\u201329436. https:\/\/doi.org\/10.1074\/JBC.M109.013193","journal-title":"J Biol Chem"},{"key":"3604_CR59","doi-asserted-by":"publisher","unstructured":"Sahoo B, Arduini I, Drombosky KW, Kodali R, Sanders LH, Greenamyre JT, Wetzel R (2016) Folding landscape of mutant huntingtin exon1: diffusible multimers, oligomers and fibrils, and no detectable monomer. PLoS One 11(6):e0155747. https:\/\/doi.org\/10.1371\/journal.pone.0155747","DOI":"10.1371\/journal.pone.0155747"},{"key":"3604_CR60","doi-asserted-by":"publisher","unstructured":"Moore BA, Barnett JE (2017) Normal function of huntingtin. Case Stud Clin Psychol Sci Bridg Gap Sci Pract: 243\u2013273. https:\/\/doi.org\/10.1093\/MED\/9780199929146.003.0011","DOI":"10.1093\/MED\/9780199929146.003.0011"},{"key":"3604_CR61","doi-asserted-by":"publisher","first-page":"2600","DOI":"10.1093\/HMG\/DDM217","volume":"16","author":"RS Atwal","year":"2007","unstructured":"Atwal RS, Xia J, Pinchev D et al (2007) Huntingtin has a membrane association signal that can modulate huntingtin aggregation, nuclear entry and toxicity. Hum Mol Genet 16:2600\u20132615. https:\/\/doi.org\/10.1093\/HMG\/DDM217","journal-title":"Hum Mol Genet"},{"key":"3604_CR62","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1038\/NSMB.1700","volume":"16","author":"S Tam","year":"2009","unstructured":"Tam S, Spiess C, Auyeung W et al (2009) The chaperonin TRiC blocks a huntingtin sequence element that promotes the conformational switch to aggregation. Nat Struct Mol Biol 16:1279\u20131285. https:\/\/doi.org\/10.1038\/NSMB.1700","journal-title":"Nat Struct Mol Biol"},{"key":"3604_CR63","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1038\/NG1503","volume":"37","author":"J Cornett","year":"2005","unstructured":"Cornett J, Cao F, Wang CE et al (2005) Polyglutamine expansion of huntingtin impairs its nuclear export. Nat Genet 37:198\u2013204. https:\/\/doi.org\/10.1038\/NG1503","journal-title":"Nat Genet"},{"key":"3604_CR64","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1126\/SCIENCE.1092194","volume":"304","author":"JS Steffan","year":"2004","unstructured":"Steffan JS, Agrawal N, Pallos J et al (2004) SUMO modification of Huntingtin and Huntington\u2019s disease pathology. Science 304:100\u2013104. https:\/\/doi.org\/10.1126\/SCIENCE.1092194","journal-title":"Science"},{"key":"3604_CR65","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1038\/NSMB.1570","volume":"16","author":"AK Thakur","year":"2009","unstructured":"Thakur AK, Jayaraman M, Mishra R et al (2009) Polyglutamine disruption of the huntingtin exon 1 N terminus triggers a complex aggregation mechanism. Nat Struct Mol Biol 16:380\u2013389. https:\/\/doi.org\/10.1038\/NSMB.1570","journal-title":"Nat Struct Mol Biol"},{"key":"3604_CR66","doi-asserted-by":"publisher","unstructured":"Jayaraman M, Kodali R, Sahoo B, Thakur AK, Mayasundari A, Mishra R, Peterson CB, Wetzel R et al (2012) Slow amyloid nucleation via \u03b1-helix-rich oligomeric intermediates in short polyglutamine-containing huntingtin fragments. J Mol Biol 415:881\u2013899. https:\/\/doi.org\/10.1016\/J.JMB.2011.12.010","DOI":"10.1016\/J.JMB.2011.12.010"},{"key":"3604_CR67","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1016\/S0092-8674(00)80514-0","volume":"90","author":"E Scherzinger","year":"1997","unstructured":"Scherzinger E, Lurz R, Turmaine M et al (1997) Huntingtin-encoded polyglutamine expansions form amyloid-like protein aggregates in vitro and in vivo. Cell 90:549\u2013558. https:\/\/doi.org\/10.1016\/S0092-8674(00)80514-0","journal-title":"Cell"},{"key":"3604_CR68","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1515\/BC.2000.114\/MACHINEREADABLECITATION\/RIS","volume":"381","author":"EE Wanker","year":"2000","unstructured":"Wanker EE (2000) Protein aggregation and pathogenesis of Huntington\u2019s disease: mechanisms and correlations. Biol Chem 381:937\u2013942. https:\/\/doi.org\/10.1515\/BC.2000.114\/MACHINEREADABLECITATION\/RIS","journal-title":"Biol Chem"},{"key":"3604_CR69","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1111\/JNC.14853","volume":"151","author":"EE Wanker","year":"2019","unstructured":"Wanker EE, Ast A, Schindler F et al (2019) The pathobiology of perturbed mutant huntingtin protein\u2013protein interactions in Huntington\u2019s disease. J Neurochem 151:507\u2013519. https:\/\/doi.org\/10.1111\/JNC.14853","journal-title":"J Neurochem"},{"key":"3604_CR70","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1021\/BI301325Q","volume":"52","author":"M Michalek","year":"2013","unstructured":"Michalek M, Salnikov ES, Werten S, Bechinger B (2013) Membrane interactions of the amphipathic amino terminus of huntingtin. Biochemistry 52:847\u2013858. https:\/\/doi.org\/10.1021\/BI301325Q","journal-title":"Biochemistry"},{"key":"3604_CR71","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1016\/J.JMB.2012.01.030","volume":"421","author":"R Wetzel","year":"2012","unstructured":"Wetzel R (2012) Physical chemistry of polyglutamine: intriguing tales of a monotonous sequence. J Mol Biol 421:466\u2013490. https:\/\/doi.org\/10.1016\/J.JMB.2012.01.030","journal-title":"J Mol Biol"},{"key":"3604_CR72","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.1093\/HMG\/7.9.1463","volume":"7","author":"PW Faber","year":"1998","unstructured":"Faber PW, Barnes GT, Srinidhi J et al (1998) Huntingtin interacts with a family of WW domain proteins. Hum Mol Genet 7:1463\u20131474. https:\/\/doi.org\/10.1093\/HMG\/7.9.1463","journal-title":"Hum Mol Genet"},{"key":"3604_CR73","doi-asserted-by":"publisher","first-page":"14610","DOI":"10.1073\/PNAS.1301342110","volume":"110","author":"NS Caron","year":"2013","unstructured":"Caron NS, Desmond CR, Xia J, Truant R (2013) Polyglutamine domain flexibility mediates the proximity between flanking sequences in huntingtin. Proc Natl Acad Sci U S A 110:14610\u201314615. https:\/\/doi.org\/10.1073\/PNAS.1301342110","journal-title":"Proc Natl Acad Sci U S A"},{"key":"3604_CR74","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1016\/S0092-8674(00)80513-9","volume":"90","author":"SW Davies","year":"1997","unstructured":"Davies SW, Turmaine M, Cozens BA et al (1997) Formation of neuronal intranuclear inclusions underlies the neurological dysfunction in mice transgenic for the HD mutation. Cell 90:537\u2013548. https:\/\/doi.org\/10.1016\/S0092-8674(00)80513-9","journal-title":"Cell"},{"key":"3604_CR75","doi-asserted-by":"publisher","first-page":"1990","DOI":"10.1126\/SCIENCE.277.5334.1990","volume":"277","author":"M DiFiglia","year":"1997","unstructured":"DiFiglia M, Sapp E, Chase KO et al (1997) Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain. Science 277:1990\u20131993. https:\/\/doi.org\/10.1126\/SCIENCE.277.5334.1990","journal-title":"Science"},{"key":"3604_CR76","doi-asserted-by":"publisher","unstructured":"Sahl SJ, Weiss LE, Duim WC et al (2012) Cellular inclusion bodies of mutant huntingtin exon 1 obscure small fibrillar aggregate species. Sci Rep 2. https:\/\/doi.org\/10.1038\/SREP00895","DOI":"10.1038\/SREP00895"},{"key":"3604_CR77","doi-asserted-by":"publisher","first-page":"41032","DOI":"10.1074\/JBC.M205809200","volume":"277","author":"MA Poirier","year":"2002","unstructured":"Poirier MA, Li H, Macosko J et al (2002) Huntingtin spheroids and protofibrils as precursors in polyglutamine fibrilization. J Biol Chem 277:41032\u201341037. https:\/\/doi.org\/10.1074\/JBC.M205809200","journal-title":"J Biol Chem"},{"key":"3604_CR78","doi-asserted-by":"publisher","unstructured":"Buckley NJ, Johnson R, Zuccato C, Bithell A, Cattaneo E (2010) The role of REST in transcriptional and epigenetic dysregulation in Huntington\u2019s disease. Neurobiol Dis 39:28\u201339. https:\/\/doi.org\/10.1016\/j.nbd.2010.02.003","DOI":"10.1016\/j.nbd.2010.02.003"},{"key":"3604_CR79","doi-asserted-by":"publisher","unstructured":"Marcellin D, Abramowski D, Young D et al (2012) Fragments of HdhQ150 mutant huntingtin form a soluble oligomer pool that declines with aggregate deposition upon aging. Plos One 7. https:\/\/doi.org\/10.1371\/JOURNAL.PONE.0044457","DOI":"10.1371\/JOURNAL.PONE.0044457"},{"key":"3604_CR80","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1006\/JMBI.2001.4850","volume":"311","author":"S Chen","year":"2001","unstructured":"Chen S, Berthelier V, Yang W, Wetzel R (2001) Polyglutamine aggregation behavior in vitro supports a recruitment mechanism of cytotoxicity. J Mol Biol 311:173\u2013182. https:\/\/doi.org\/10.1006\/JMBI.2001.4850","journal-title":"J Mol Biol"},{"key":"3604_CR81","doi-asserted-by":"publisher","first-page":"10417","DOI":"10.1073\/PNAS.152161099","volume":"99","author":"JF Morley","year":"2002","unstructured":"Morley JF, Brignull HR, Weyers JJ, Morimoto RI (2002) The threshold for polyglutamine-expansion protein aggregation and cellular toxicity is dynamic and influenced by aging in Caenorhabditis elegans. Proc Natl Acad Sci U S A 99:10417\u201310422. https:\/\/doi.org\/10.1073\/PNAS.152161099","journal-title":"Proc Natl Acad Sci U S A"},{"key":"3604_CR82","doi-asserted-by":"publisher","first-page":"3078","DOI":"10.1016\/J.BPJ.2010.02.058","volume":"98","author":"G Ossato","year":"2010","unstructured":"Ossato G, Digman MA, Aiken C et al (2010) A two-step path to inclusion formation of huntingtin peptides revealed by number and brightness analysis. Biophys J 98:3078\u20133085. https:\/\/doi.org\/10.1016\/J.BPJ.2010.02.058","journal-title":"Biophys J"},{"key":"3604_CR83","doi-asserted-by":"publisher","first-page":"11884","DOI":"10.1073\/PNAS.182276099","volume":"99","author":"S Chen","year":"2002","unstructured":"Chen S, Ferrone FA, Wetzel R (2002) Huntington\u2019s disease age-of-onset linked to polyglutamine aggregation nucleation. Proc Natl Acad Sci U S A 99:11884\u201311889. https:\/\/doi.org\/10.1073\/PNAS.182276099","journal-title":"Proc Natl Acad Sci U S A"},{"key":"3604_CR84","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1177\/1039856218791036","volume":"26","author":"AMY Goh","year":"2018","unstructured":"Goh AMY, Wibawa P, Loi SM et al (2018) Huntington\u2019s disease: neuropsychiatric manifestations of Huntington\u2019s disease. Australas Psychiatry 26:366\u2013375. https:\/\/doi.org\/10.1177\/1039856218791036","journal-title":"Australas Psychiatry"},{"key":"3604_CR85","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1212\/01.WNL.0000052992.58107.67","volume":"60","author":"VL Wheelock","year":"2003","unstructured":"Wheelock VL, Tempkin T, Marder K et al (2003) Predictors of nursing home placement in Huntington disease. Neurology 60:998\u20131001. https:\/\/doi.org\/10.1212\/01.WNL.0000052992.58107.67","journal-title":"Neurology"},{"key":"3604_CR86","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1042\/BJ20071619","volume":"412","author":"S Imarisio","year":"2008","unstructured":"Imarisio S, Carmichael J, Korolchuk V et al (2008) Huntington\u2019s disease: from pathology and genetics to potential therapies. Biochem J 412:191\u2013209. https:\/\/doi.org\/10.1042\/BJ20071619","journal-title":"Biochem J"},{"key":"3604_CR87","doi-asserted-by":"publisher","unstructured":"Wang H, Chen X, Li Y et al (2010) Tetrabenazine is neuroprotective in Huntington\u2019s disease mice. Mol Neurodegener 5. https:\/\/doi.org\/10.1186\/1750-1326-5-18","DOI":"10.1186\/1750-1326-5-18"},{"key":"3604_CR88","doi-asserted-by":"publisher","unstructured":"Kumar A, Kumar V, Singh K et al (2020) Therapeutic advances for Huntington\u2019s disease. Brain Sci 10. https:\/\/doi.org\/10.3390\/BRAINSCI10010043","DOI":"10.3390\/BRAINSCI10010043"},{"key":"3604_CR89","doi-asserted-by":"publisher","first-page":"123","DOI":"10.2147\/TCRM.S17152","volume":"7","author":"M de Tommaso","year":"2011","unstructured":"de Tommaso M, Serpino C, Sciruicchio V (2011) Management of Huntington\u2019s disease: role of tetrabenazine. Ther Clin Risk Manag 7:123. https:\/\/doi.org\/10.2147\/TCRM.S17152","journal-title":"Ther Clin Risk Manag"},{"key":"3604_CR90","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1007\/S40265-016-0670-4","volume":"77","author":"EM Coppen","year":"2017","unstructured":"Coppen EM, Roos RAC (2017) Current Pharmacological approaches to reduce chorea in Huntington\u2019s disease. Drugs 77:29\u201346. https:\/\/doi.org\/10.1007\/S40265-016-0670-4","journal-title":"Drugs"},{"key":"3604_CR91","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/NRNEUROL.2017.148","volume":"14","author":"C Rinaldi","year":"2018","unstructured":"Rinaldi C, Wood MJA (2018) Antisense oligonucleotides: the next frontier for treatment of neurological disorders. Nat Rev Neurol 14:9\u201322. https:\/\/doi.org\/10.1038\/NRNEUROL.2017.148","journal-title":"Nat Rev Neurol"},{"key":"3604_CR92","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1016\/J.IT.2015.04.007","volume":"36","author":"A Crotti","year":"2015","unstructured":"Crotti A, Glass CK (2015) The choreography of neuroinflammation in Huntington\u2019s disease. Trends Immunol 36:364\u2013373. https:\/\/doi.org\/10.1016\/J.IT.2015.04.007","journal-title":"Trends Immunol"},{"key":"3604_CR93","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/J.NEURES.2005.06.021","volume":"53","author":"YL Wang","year":"2005","unstructured":"Wang YL, Liu W, Wada E et al (2005) Clinico-pathological rescue of a model mouse of Huntington\u2019s disease by siRNA. Neurosci Res 53:241\u2013249. https:\/\/doi.org\/10.1016\/J.NEURES.2005.06.021","journal-title":"Neurosci Res"},{"issue":"10","key":"3604_CR94","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1038\/nm1076","volume":"108","author":"H Xia","year":"2004","unstructured":"Xia H, Mao Q, Eliason SL et al (2004) (2004) RNAi suppresses polyglutamine-induced neurodegeneration in a model of spinocerebellar ataxia. Nat Med 108(10):816\u2013820. https:\/\/doi.org\/10.1038\/nm1076","journal-title":"Nat Med"},{"key":"3604_CR95","doi-asserted-by":"publisher","first-page":"7195","DOI":"10.1073\/PNAS.1231012100\/SUPPL_FILE\/1012FIG5.JPG","volume":"100","author":"VM Miller","year":"2003","unstructured":"Miller VM, Xia H, Marrs GL et al (2003) Allele-specific silencing of dominant disease genes. Proc Natl Acad Sci U S A 100:7195\u20137200. https:\/\/doi.org\/10.1073\/PNAS.1231012100\/SUPPL_FILE\/1012FIG5.JPG","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"36","key":"3604_CR96","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1038\/ng1362","volume":"366","author":"B Ravikumar","year":"2004","unstructured":"Ravikumar B, Vacher C, Berger Z et al (2004) (2004) Inhibition of mTOR induces autophagy and reduces toxicity of polyglutamine expansions in fly and mouse models of Huntington disease. Nat Genet 366(36):585\u2013595. https:\/\/doi.org\/10.1038\/ng1362","journal-title":"Nat Genet"},{"key":"3604_CR97","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1093\/HMG\/DDI458","volume":"15","author":"Z Berger","year":"2006","unstructured":"Berger Z, Ravikumar B, Menzies FM et al (2006) Rapamycin alleviates toxicity of different aggregate-prone proteins. Hum Mol Genet 15:433\u2013442. https:\/\/doi.org\/10.1093\/HMG\/DDI458","journal-title":"Hum Mol Genet"},{"key":"3604_CR98","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1016\/S0896-6273(00)80716-3","volume":"22","author":"I S\u00e1nchez","year":"1999","unstructured":"S\u00e1nchez I, Chi-Jie X, Peter J et al (1999) Caspase-8 is required for cell death induced by expanded polyglutamine repeats. Neuron 22:623\u2013633. https:\/\/doi.org\/10.1016\/S0896-6273(00)80716-3","journal-title":"Neuron"},{"key":"3604_CR99","doi-asserted-by":"publisher","first-page":"1523","DOI":"10.1038\/APS.2010.186","volume":"31","author":"PF Wu","year":"2010","unstructured":"Wu PF, Zhang Z, Wang F, Chen JG (2010) Natural compounds from traditional medicinal herbs in the treatment of cerebral ischemia\/reperfusion injury. Acta Pharmacol Sin 31:1523\u20131531. https:\/\/doi.org\/10.1038\/APS.2010.186","journal-title":"Acta Pharmacol Sin"},{"key":"3604_CR100","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1016\/j.jep.2007.07.016","volume":"113","author":"M Adams","year":"2007","unstructured":"Adams M, Gm\u00fcnder F, Hamburger M (2007) Plants traditionally used in age related brain disorders\u2014A survey of ethnobotanical literature. J Ethnopharmacol 113:363\u2013381. https:\/\/doi.org\/10.1016\/j.jep.2007.07.016","journal-title":"J Ethnopharmacol"},{"key":"3604_CR101","doi-asserted-by":"publisher","first-page":"140","DOI":"10.4103\/0973-7847.162137","volume":"9","author":"T Isah","year":"2015","unstructured":"Isah T (2015) Rethinking Ginkgo biloba L.: Medicinal uses and conservation. Pharmacogn Rev 9:140. https:\/\/doi.org\/10.4103\/0973-7847.162137","journal-title":"Pharmacogn Rev"},{"key":"3604_CR102","doi-asserted-by":"publisher","first-page":"4987","DOI":"10.1016\/J.BMC.2005.06.014","volume":"13","author":"K Nakanishi","year":"2005","unstructured":"Nakanishi K (2005) Terpene trilactones from Gingko biloba: from ancient times to the 21st century. Bioorg Med Chem 13:4987\u20135000. https:\/\/doi.org\/10.1016\/J.BMC.2005.06.014","journal-title":"Bioorg Med Chem"},{"key":"3604_CR103","doi-asserted-by":"publisher","unstructured":"Mahadevan S, Park Y (2007) Multifaceted therapeutic benefits of Ginkgo biloba L.: chemistry, efficacy, safety, and uses. J Food Sci 73:R14\u2013R19. https:\/\/doi.org\/10.1111\/j.1750-3841.2007.00597.x","DOI":"10.1111\/j.1750-3841.2007.00597.x"},{"key":"3604_CR104","doi-asserted-by":"publisher","first-page":"25","DOI":"10.2174\/1389450003349380","volume":"1","author":"F DeFeudis","year":"2000","unstructured":"DeFeudis F, Drieu K (2000) Ginkgo biloba extract (EGb 761) and CNS functions: basic studies and clinical applications. Curr Drug Targets 1:25\u201358. https:\/\/doi.org\/10.2174\/1389450003349380","journal-title":"Curr Drug Targets"},{"key":"3604_CR105","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1007\/S00253-003-1527-9","volume":"64","author":"JV Smith","year":"2004","unstructured":"Smith JV, Luo Y (2004) Studies on molecular mechanisms of Ginkgo biloba extract. Appl Microbiol Biotechnol 64:465\u2013472. https:\/\/doi.org\/10.1007\/S00253-003-1527-9","journal-title":"Appl Microbiol Biotechnol"},{"key":"3604_CR106","doi-asserted-by":"publisher","unstructured":"Singh SK, Srivastav S, Castellani RJ, Plascencia-Villa G, Perry G (2019) Neuroprotective and antioxidant effect of Ginkgo biloba extract against AD and other neurological disorders. Neurotherapeutics 16(3):666-674. https:\/\/doi.org\/10.1007\/s13311-019-00767-8","DOI":"10.1007\/s13311-019-00767-8"},{"key":"3604_CR107","doi-asserted-by":"publisher","unstructured":"Pietri S, Maurelli E, Drieu K, Culcasi M (1997) Cardioprotective and anti-oxidant effects of the terpenoid constituents of Ginkgo biloba extract (EGb 761). J Mol Cell Cardiol 29:733\u2013742. https:\/\/doi.org\/10.1006\/JMCC.1996.0316","DOI":"10.1006\/JMCC.1996.0316"},{"issue":"2","key":"3604_CR108","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1002\/bdd.2350","volume":"44","author":"J Bai","year":"2023","unstructured":"Bai J, Zhang C (2023) Metabolic interaction between biflavonoids in Ginkgo biloba leaves and tacrolimus. Biopharm Drug Dispos 44(2):157\u2013164. https:\/\/doi.org\/10.1002\/bdd.2350","journal-title":"Biopharm Drug Dispos"},{"key":"3604_CR109","doi-asserted-by":"publisher","unstructured":"Mahdy HM, Tadros MG, Mohamed MR et al (2011) The effect of Ginkgo biloba extract on 3-nitropropionic acid-induced neurotoxicity in rats. 59:770\u2013778. https:\/\/doi.org\/10.1016\/J.NEUINT.2011.07.012","DOI":"10.1016\/J.NEUINT.2011.07.012"},{"key":"3604_CR110","doi-asserted-by":"publisher","first-page":"1","DOI":"10.47552\/ijam.v6i1.553","volume":"6","author":"T Manisha","year":"2015","unstructured":"Manisha T, Sisir Kumar M, Reetu S (2015) Rasayana as a public health tool in communicable diseases: a review. Int J Ayurvedic Med 6:1\u20137","journal-title":"Int J Ayurvedic Med"},{"key":"3604_CR111","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1211\/JPP.57.9.0018","volume":"57","author":"A Soumyanath","year":"2005","unstructured":"Soumyanath A, Zhong Y-P, Yu X et al (2005) Centella asiatica accelerates nerve regeneration upon oral administration and contains multiple active fractions increasing neurite elongation in-vitro. J Pharm Pharmacol 57:1221\u20131229. https:\/\/doi.org\/10.1211\/JPP.57.9.0018","journal-title":"J Pharm Pharmacol"},{"key":"3604_CR112","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1016\/S0308-8146(02)00498-3","volume":"81","author":"MK Zainol","year":"2003","unstructured":"Zainol MK, Abd-Hamid A, Yusof S, Muse R (2003) Antioxidative activity and total phenolic compounds of leaf, root and petiole of four accessions of Centella asiatica (L.) Urban. Food Chem 81:575\u2013581. https:\/\/doi.org\/10.1016\/S0308-8146(02)00498-3","journal-title":"Food Chem"},{"key":"3604_CR113","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/J.FOODCHEM.2005.10.022","volume":"100","author":"M Hussin","year":"2007","unstructured":"Hussin M, Abdul-Hamid A, Mohamad S et al (2007) Protective effect of Centella asiatica extract and powder on oxidative stress in rats. Food Chem 100:535\u2013541. https:\/\/doi.org\/10.1016\/J.FOODCHEM.2005.10.022","journal-title":"Food Chem"},{"key":"3604_CR114","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1016\/S0031-9422(00)85884-7","volume":"8","author":"B Singh","year":"1969","unstructured":"Singh B, Rastogi RP (1969) A reinvestigation of the triterpenes of Centella asiatica. Phytochemistry 8:917\u2013921. https:\/\/doi.org\/10.1016\/S0031-9422(00)85884-7","journal-title":"Phytochemistry"},{"key":"3604_CR115","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1016\/J.FITOTE.2007.03.016","volume":"78","author":"D Randriamampionona","year":"2007","unstructured":"Randriamampionona D, Diallo B, Rakotoniriana F et al (2007) Comparative analysis of active constituents in Centella asiatica samples from Madagascar: application for ex situ conservation and clonal propagation. Fitoterapia 78:482\u2013489. https:\/\/doi.org\/10.1016\/J.FITOTE.2007.03.016","journal-title":"Fitoterapia"},{"key":"3604_CR116","doi-asserted-by":"publisher","first-page":"1385","DOI":"10.1016\/S0031-9422(00)85642-3","volume":"7","author":"B Singh","year":"1968","unstructured":"Singh B, Rastogi RP (1968) Chemical examination of Centella asiatica linn\u2014III\u202f: Constitution of brahmic acid. Phytochemistry 7:1385\u20131393. https:\/\/doi.org\/10.1016\/S0031-9422(00)85642-3","journal-title":"Phytochemistry"},{"key":"3604_CR117","doi-asserted-by":"publisher","first-page":"948","DOI":"10.1016\/J.NEURO.2008.09.009","volume":"29","author":"GK Shinomol","year":"2008","unstructured":"Shinomol GK, Muralidhara (2008) Prophylactic neuroprotective property of Centella asiatica against 3-nitropropionic acid induced oxidative stress and mitochondrial dysfunctions in brain regions of prepubertal mice. Neurotoxicol 29:948\u2013957. https:\/\/doi.org\/10.1016\/J.NEURO.2008.09.009","journal-title":"Neurotoxicol"},{"key":"3604_CR118","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1016\/J.BIOTECHADV.2015.03.001","volume":"33","author":"YJ Kim","year":"2015","unstructured":"Kim YJ, Zhang D, Yang DC (2015) Biosynthesis and biotechnological production of ginsenosides. Biotechnol Adv 33:717\u2013735. https:\/\/doi.org\/10.1016\/J.BIOTECHADV.2015.03.001","journal-title":"Biotechnol Adv"},{"key":"3604_CR119","doi-asserted-by":"publisher","first-page":"41","DOI":"10.2174\/157488912798842278","volume":"7","author":"O Sagredo","year":"2012","unstructured":"Sagredo O, Ruth Pazos M, Valdeolivas S, Fern\u00e1ndez-Ruiz J (2012) Cannabinoids: novel medicines for the treatment of Huntington\u2019s disease. Recent Pat CNS Drug Discov 7:41\u201348. https:\/\/doi.org\/10.2174\/157488912798842278","journal-title":"Recent Pat CNS Drug Discov"},{"key":"3604_CR120","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1021\/CN200114W","volume":"3","author":"S Valdeolivas","year":"2012","unstructured":"Valdeolivas S, Satta V, Pertwee RG et al (2012) Sativex-like combination of phytocannabinoids is neuroprotective in malonate-lesioned rats, an inflammatory model of Huntington\u2019s disease: role of CB1 and CB2 receptors. ACS Chem Neurosci 3:400\u2013406. https:\/\/doi.org\/10.1021\/CN200114W","journal-title":"ACS Chem Neurosci"},{"key":"3604_CR121","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.1002\/GLIA.20838","volume":"57","author":"O Sagredo","year":"2009","unstructured":"Sagredo O, Gonz\u00e1lez S, Aroyo I et al (2009) Cannabinoid CB2 receptor agonists protect the striatum against malonate toxicity: relevance for Huntington\u2019s disease. Glia 57:1154\u20131167. https:\/\/doi.org\/10.1002\/GLIA.20838","journal-title":"Glia"},{"key":"3604_CR122","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1097\/00001756-200305060-00007","volume":"14","author":"I Lastres-Becker","year":"2003","unstructured":"Lastres-Becker I, Bizat N, Boyer F et al (2003) Effects of cannabinoids in the rat model of Huntington\u2019s disease generated by an intrastriatal injection of malonate. NeuroReport 14:813\u2013816. https:\/\/doi.org\/10.1097\/00001756-200305060-00007","journal-title":"NeuroReport"},{"key":"3604_CR123","doi-asserted-by":"publisher","unstructured":"Jang JH, Son Y, Kang SS et al (2015) Neuropharmacological potential of gastrodia elata blume and its components. Evid Based Complement Alternat Med 2015. https:\/\/doi.org\/10.1155\/2015\/309261","DOI":"10.1155\/2015\/309261"},{"key":"3604_CR124","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/J.JEP.2011.08.064","volume":"138","author":"CF Tsai","year":"2011","unstructured":"Tsai CF, Huang CL, Lin YL et al (2011) The neuroprotective effects of an extract of Gastrodia elata. J Ethnopharmacol 138:119\u2013125. https:\/\/doi.org\/10.1016\/J.JEP.2011.08.064","journal-title":"J Ethnopharmacol"},{"key":"3604_CR125","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1111\/NEUP.12115","volume":"34","author":"Y Hu","year":"2014","unstructured":"Hu Y, Li C, Shen W (2014) Gastrodin alleviates memory deficits and reduces neuropathology in a mouse model of Alzheimer\u2019s disease. Neuropathology 34:370\u2013377. https:\/\/doi.org\/10.1111\/NEUP.12115","journal-title":"Neuropathology"},{"key":"3604_CR126","doi-asserted-by":"publisher","unstructured":"Doo AR, Kim SN, Hahm DH et al (2014) Gastrodia elata Blume alleviates L-DOPA-induced dyskinesia by normalizing FosB and ERK activation in a 6-OHDA-lesioned Parkinson\u2019s disease mouse model. BMC Complement Altern Med 14. https:\/\/doi.org\/10.1186\/1472-6882-14-107","DOI":"10.1186\/1472-6882-14-107"},{"key":"3604_CR127","doi-asserted-by":"publisher","unstructured":"Wang Q, Shen L, Ma S, Chen M, Lin X, Hong Y, Liang S, Feng Y (2015) Effects of Ligusticum chuanxiong and Gastrodia elata on blood-brain barrier permeability in migraine rats. Int J Pharm Sci Res 70:421\u20136. https:\/\/doi.org\/10.1691\/ph.2015.4852","DOI":"10.1691\/ph.2015.4852"},{"key":"3604_CR128","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.1248\/BPB.28.1016","volume":"28","author":"SJ Yu","year":"2005","unstructured":"Yu SJ, Kim JR, Lee CK et al (2005) Gastrodia elata blume and an active component, p-hydroxybenzyl alcohol reduce focal ischemic brain injury through antioxidant related gene expressions. Biol Pharm Bull 28:1016\u20131020. https:\/\/doi.org\/10.1248\/BPB.28.1016","journal-title":"Biol Pharm Bull"},{"key":"3604_CR129","doi-asserted-by":"publisher","first-page":"1593","DOI":"10.1142\/S0192415X15500901","volume":"43","author":"LY Wu","year":"2015","unstructured":"Wu LY, Chen WC, Tsai FS et al (2015) p-Hydroxybenzyl alcohol, an active phenolic ingredient of gastrodia elata, reverses the cycloheximide-induced memory deficit by activating the adrenal gland in rats. Am J Chin Med 43:1593\u20131604. https:\/\/doi.org\/10.1142\/S0192415X15500901","journal-title":"Am J Chin Med"},{"key":"3604_CR130","doi-asserted-by":"publisher","first-page":"2468","DOI":"10.1016\/J.JPROT.2012.02.029","volume":"75","author":"A Manavalan","year":"2012","unstructured":"Manavalan A, Feng L, Sze SK et al (2012) New insights into the brain protein metabolism of Gastrodia elata-treated rats by quantitative proteomics. J Proteomics 75:2468\u20132479. https:\/\/doi.org\/10.1016\/J.JPROT.2012.02.029","journal-title":"J Proteomics"},{"key":"3604_CR131","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/J.JEP.2011.08.075","volume":"138","author":"CL Huang","year":"2011","unstructured":"Huang CL, Yang JM, Wang KC et al (2011) Gastrodia elata prevents huntingtin aggregations through activation of the adenosine A2A receptor and ubiquitin proteasome system. J Ethnopharmacol 138:162\u2013168. https:\/\/doi.org\/10.1016\/J.JEP.2011.08.075","journal-title":"J Ethnopharmacol"},{"key":"3604_CR132","doi-asserted-by":"publisher","unstructured":"Jiang W, Wei W, Gaertig MA et al (2015) Therapeutic effect of berberine on Huntington\u2019s disease transgenic mouse model. PLoS One 10. https:\/\/doi.org\/10.1371\/JOURNAL.PONE.0134142","DOI":"10.1371\/JOURNAL.PONE.0134142"},{"key":"3604_CR133","doi-asserted-by":"publisher","unstructured":"Chen CG, Hung TH, Lee CY et al (2014) Berberine protects against neuronal damage via suppression of glia-mediated inflammation in traumatic brain injury. PLoS One 9:e115694.\u00a0https:\/\/doi.org\/10.1371\/JOURNAL.PONE.0115694","DOI":"10.1371\/JOURNAL.PONE.0115694"},{"key":"3604_CR134","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/J.BRAINRES.2014.02.021","volume":"1557","author":"EN Sim\u00f5es Pires","year":"2014","unstructured":"Sim\u00f5es Pires EN, Frozza RL, Hoppe JB et al (2014) Berberine was neuroprotective against an in vitro model of brain ischemia: survival and apoptosis pathways involved. Brain Res 1557:26\u201333. https:\/\/doi.org\/10.1016\/J.BRAINRES.2014.02.021","journal-title":"Brain Res"},{"key":"3604_CR135","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1016\/J.JGR.2021.11.003","volume":"46","author":"KF Hua","year":"2022","unstructured":"Hua KF, Chao AC, Lin TY et al (2022) Ginsenoside compound K reduces the progression of Huntington\u2019s disease via the inhibition of oxidative stress and overactivation of the ATM\/AMPK pathway. J Ginseng Res 46:572\u2013584. https:\/\/doi.org\/10.1016\/J.JGR.2021.11.003","journal-title":"J Ginseng Res"},{"key":"3604_CR136","doi-asserted-by":"publisher","unstructured":"Solanki I, Parihar P, Mansuri ML, Parihar MS (2015) Flavonoid-based therapies in the early management of neurodegenerative diseases. Adv Nutr 6:64\u201372. https:\/\/doi.org\/10.3945\/an.114.007500","DOI":"10.3945\/an.114.007500"},{"key":"3604_CR137","doi-asserted-by":"publisher","first-page":"1944","DOI":"10.1016\/J.PNPBP.2011.09.005","volume":"35","author":"I Tasset","year":"2011","unstructured":"Tasset I, Ag\u00fcera E, Olmo-Camacho R et al (2011) Melatonin improves 3-nitropropionic acid induced behavioral alterations and neurotrophic factors levels. Prog Neuropsychopharmacol Biol Psychiatry 35:1944\u20131949. https:\/\/doi.org\/10.1016\/J.PNPBP.2011.09.005","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"3604_CR138","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/J.BRAINRES.2005.03.053","volume":"1046","author":"E Nam","year":"2005","unstructured":"Nam E, Seung ML, Seong EK et al (2005) Melatonin protects against neuronal damage induced by 3-nitropropionic acid in rat striatum. Brain Res 1046:90\u201396. https:\/\/doi.org\/10.1016\/J.BRAINRES.2005.03.053","journal-title":"Brain Res"},{"key":"3604_CR139","doi-asserted-by":"publisher","first-page":"2522","DOI":"10.1016\/J.FCT.2009.07.011","volume":"47","author":"P Kumar","year":"2009","unstructured":"Kumar P, Kumar A (2009) Effect of lycopene and epigallocatechin-3-gallate against 3-nitropropionic acid induced cognitive dysfunction and glutathione depletion in rat: a novel nitric oxide mechanism. Food Chem Toxicol 47:2522\u20132530. https:\/\/doi.org\/10.1016\/J.FCT.2009.07.011","journal-title":"Food Chem Toxicol"},{"key":"3604_CR140","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1016\/J.NEUINT.2011.05.009","volume":"59","author":"S Mu","year":"2011","unstructured":"Mu S, Ouyang L, Liu B et al (2011) Protective effect of melatonin on 3-NP induced striatal interneuron injury in rats. Neurochem Int 59:224\u2013234. https:\/\/doi.org\/10.1016\/J.NEUINT.2011.05.009","journal-title":"Neurochem Int"},{"key":"3604_CR141","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1007\/BF03180581","volume":"65","author":"I Tasset","year":"2009","unstructured":"Tasset I, Esp\u00ednola C, Medina FJ et al (2009) Neuroprotective effect of carvedilol and melatonin on 3-nitropropionic acid-induced neurotoxicity in neuroblastoma. J Physiol Biochem 65:291\u2013296. https:\/\/doi.org\/10.1007\/BF03180581","journal-title":"J Physiol Biochem"},{"key":"3604_CR142","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/J.BBR.2014.01.048","volume":"264","author":"J Chakraborty","year":"2014","unstructured":"Chakraborty J, Nthenge-Ngumbau DN, Rajamma U, Mohanakumar KP (2014) Melatonin protects against behavioural dysfunctions and dendritic spine damage in 3-nitropropionic acid-induced rat model of Huntington\u2019s disease. Behav Brain Res 264:91\u2013104. https:\/\/doi.org\/10.1016\/J.BBR.2014.01.048","journal-title":"Behav Brain Res"},{"key":"3604_CR143","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/J.NEUROSCIENCE.2012.07.060","volume":"227","author":"K Gopinath","year":"2012","unstructured":"Gopinath K, Sudhandiran G (2012) Naringin modulates oxidative stress and inflammation in 3-nitropropionic acid-induced neurodegeneration through the activation of nuclear factor-erythroid 2-related factor-2 signalling pathway. Neuroscience 227:134\u2013143. https:\/\/doi.org\/10.1016\/J.NEUROSCIENCE.2012.07.060","journal-title":"Neuroscience"},{"key":"3604_CR144","doi-asserted-by":"publisher","first-page":"1066","DOI":"10.1016\/J.NEUINT.2011.08.022","volume":"59","author":"K Gopinath","year":"2011","unstructured":"Gopinath K, Prakash D, Sudhandiran G (2011) Neuroprotective effect of naringin, a dietary flavonoid against 3-nitropropionic acid-induced neuronal apoptosis. Neurochem Int 59:1066\u20131073. https:\/\/doi.org\/10.1016\/J.NEUINT.2011.08.022","journal-title":"Neurochem Int"},{"key":"3604_CR145","doi-asserted-by":"publisher","first-page":"1615","DOI":"10.1007\/S11064-012-0756-7","volume":"37","author":"W Rong","year":"2012","unstructured":"Rong W, Wang J, Liu X et al (2012) Naringin treatment improves functional recovery by increasing BDNF and VEGF expression, inhibiting neuronal apoptosis after spinal cord injury. Neurochem Res 37:1615\u20131623. https:\/\/doi.org\/10.1007\/S11064-012-0756-7","journal-title":"Neurochem Res"},{"key":"3604_CR146","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1139\/CJPP-2015-0035","volume":"94","author":"K Gopinath","year":"2016","unstructured":"Gopinath K, Sudhandiran G (2016) Protective effect of naringin on 3-nitropropionic acid-induced neurodegeneration through the modulation of matrix metalloproteinases and glial fibrillary acidic protein. Can J Physiol Pharmacol 94:65\u201371. https:\/\/doi.org\/10.1139\/CJPP-2015-0035","journal-title":"Can J Physiol Pharmacol"},{"key":"3604_CR147","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1007\/S11010-015-2525-9","volume":"409","author":"G Kulasekaran","year":"2015","unstructured":"Kulasekaran G, Ganapasam S (2015) Neuroprotective efficacy of naringin on 3-nitropropionic acid-induced mitochondrial dysfunction through the modulation of Nrf2 signaling pathway in PC12 cells. Mol Cell Biochem 409:199\u2013211. https:\/\/doi.org\/10.1007\/S11010-015-2525-9","journal-title":"Mol Cell Biochem"},{"key":"3604_CR148","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/J.PNPBP.2012.08.018","volume":"40","author":"KM Denny Joseph","year":"2013","unstructured":"Denny Joseph KM, Muralidhara (2013) Enhanced neuroprotective effect of fish oil in combination with quercetin against 3-nitropropionic acid induced oxidative stress in rat brain. Prog Neuropsychopharmacol Biol Psychiatry 40:83\u201392. https:\/\/doi.org\/10.1016\/J.PNPBP.2012.08.018","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"3604_CR149","doi-asserted-by":"publisher","unstructured":"Ehrnhoefer DE, Duennwald ML, Markovic P, Wacker JL, Engemann S, Roark M, Legleiter J, Lawrence Marsh J et al (2006) Green tea (\u2212)-epigallocatechin-gallate modulates early events in huntingtin misfolding and reduces toxicity in Huntington\u2019s disease models. Hum Mol Genet 15:2743\u20132751. https:\/\/doi.org\/10.1093\/hmg\/ddl210","DOI":"10.1093\/hmg\/ddl210"},{"key":"3604_CR150","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/0378-8741(92)90057-X","volume":"36","author":"L Chang-Xiao","year":"1992","unstructured":"Chang-Xiao L, Pei-Gen X (1992) Recent advances on ginseng research in China. J Ethnopharmacol 36:27\u201338. https:\/\/doi.org\/10.1016\/0378-8741(92)90057-X","journal-title":"J Ethnopharmacol"},{"key":"3604_CR151","doi-asserted-by":"publisher","first-page":"293","DOI":"10.2174\/157016109788340767","volume":"7","author":"J-M Lu","year":"2009","unstructured":"Lu J-M, Yao Q, Chen C (2009) Ginseng compounds: an update on their molecular mechanisms and medical applications. Curr Vasc Pharmacol 7:293\u2013302. https:\/\/doi.org\/10.2174\/157016109788340767","journal-title":"Curr Vasc Pharmacol"},{"key":"3604_CR152","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1254\/JPHS.CRJ05010X","volume":"100","author":"K Radad","year":"2006","unstructured":"Radad K, Gille G, Liu L, Rausch WD (2006) Use of ginseng in medicine with emphasis on neurodegenerative disorders. J Pharmacol Sci 100:175\u2013186. https:\/\/doi.org\/10.1254\/JPHS.CRJ05010X","journal-title":"J Pharmacol Sci"},{"key":"3604_CR153","doi-asserted-by":"publisher","unstructured":"Li M, Qian M, Jiang Q, Tan B, Yin Y, Han X (2023) Evidence of flavonoids on disease prevention. Antioxidants (Basel) 12(2):527. https:\/\/doi.org\/10.3390\/antiox12020527","DOI":"10.3390\/antiox12020527"},{"key":"3604_CR154","doi-asserted-by":"publisher","unstructured":"Sadeghi N, Oveisi MR, Hajimahmoodi M et al (2010) The contents of sesamol in iranian sesame seeds. Iran J Pharm Res 0:101\u2013105. https:\/\/doi.org\/10.22037\/IJPR.2010.796","DOI":"10.22037\/IJPR.2010.796"},{"key":"3604_CR155","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/S0304-3835(99)00369-9","volume":"150","author":"YS Keum","year":"2000","unstructured":"Keum YS, Park KK, Lee JM et al (2000) Antioxidant and anti-tumor promoting activities of the methanol extract of heat-processed ginseng. Cancer Lett 150:41\u201348. https:\/\/doi.org\/10.1016\/S0304-3835(99)00369-9","journal-title":"Cancer Lett"},{"key":"3604_CR156","doi-asserted-by":"publisher","unstructured":"Shimizu S, Fujii G, Takahashi M, Nakanishi R, Komiya M, Shimura M, Noma N, Onuma W et al (2014) Sesamol suppresses cyclooxygenase-2 transcriptional activity in colon cancer cells and modifies intestinal polyp development in ApcMin\/+ mice. J Clin Biochem Nutr 54:95\u2013101. https:\/\/doi.org\/10.3164\/jcbn.13-91","DOI":"10.3164\/jcbn.13-91"},{"key":"3604_CR157","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1002\/(sici)1097-4547(19981001)54:1%3C123::aid-jnr13%3E3.0.co;2-8","volume":"53","author":"Y Kim","year":"1998","unstructured":"Kim Y, Kim S, Markelonis G, Oh T (1998) Ginsenosides Rb1 and Rg3 protect cultured rat cortical cells from glutamate-induced neurodegeneration. J Neurosci Res 53:426\u2013432. https:\/\/doi.org\/10.1002\/(sici)1097-4547(19981001)54:1%3C123::aid-jnr13%3E3.0.co;2-8","journal-title":"J Neurosci Res"},{"key":"3604_CR158","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1016\/J.NEUROPHARM.2004.12.013","volume":"48","author":"JH Kim","year":"2005","unstructured":"Kim JH, Kim S, Yoon IS et al (2005) Protective effects of ginseng saponins on 3-nitropropionic acid-induced striatal degeneration in rats. Neuropharmacology 48:743\u2013756. https:\/\/doi.org\/10.1016\/J.NEUROPHARM.2004.12.013","journal-title":"Neuropharmacology"},{"key":"3604_CR159","doi-asserted-by":"publisher","first-page":"466","DOI":"10.3109\/01480545.2013.776583","volume":"36","author":"BD Shivasharan","year":"2013","unstructured":"Shivasharan BD, Nagakannan P, Thippeswamy BS et al (2013) Protective effect of Calendula officinalis Linn. flowers against 3-nitropropionic acid induced experimental Huntington\u2019s disease in rats. Drug Chem Toxicol 36:466\u2013473. https:\/\/doi.org\/10.3109\/01480545.2013.776583","journal-title":"Drug Chem Toxicol"},{"key":"3604_CR160","doi-asserted-by":"publisher","unstructured":"Kaur M, Prakash A, Kalia AN (2016) Neuroprotective potential of antioxidant potent fractions from Convolvulus pluricaulis Chois. in 3-nitropropionic acid challenged rats. 19:70\u201378. https:\/\/doi.org\/10.1179\/1476830515Y.0000000022","DOI":"10.1179\/1476830515Y.0000000022"},{"key":"3604_CR161","doi-asserted-by":"publisher","unstructured":"Piwowar A, Rembia\u0142kowska N, Rorbach-Dolata A et al (2020) Anemarrhenae asphodeloides rhizoma extract enriched in mangiferin protects PC12 cells against a neurotoxic agent-3-nitropropionic acid. 21:2510. https:\/\/doi.org\/10.3390\/IJMS21072510","DOI":"10.3390\/IJMS21072510"},{"key":"3604_CR162","doi-asserted-by":"publisher","unstructured":"Al-Sabahi BN, Fatope MO, Essa MM et al. Pomegranate seed oil: Effect on 3-nitropropionic acid-induced neurotoxicity in PC12 cells and elucidation of unsaturated fatty acids composition. 20:40\u201348. https:\/\/doi.org\/10.1179\/1476830514Y.0000000155","DOI":"10.1179\/1476830514Y.0000000155"},{"key":"3604_CR163","doi-asserted-by":"publisher","unstructured":"Malik J, Karan M, Dogra R (2017) Ameliorating effect of Celastrus paniculatus standardized extract and its fractions on 3-nitropropionic acid induced neuronal damage in rats: possible antioxidant mechanism. 55:980\u2013990. https:\/\/doi.org\/10.1080\/13880209.2017.1285945","DOI":"10.1080\/13880209.2017.1285945"},{"key":"3604_CR164","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1089\/JMF.2008.0028","volume":"12","author":"P Kumar","year":"2009","unstructured":"Kumar P, Kumar A (2009) Possible neuroprotective effect of Withania somnifera root extract against 3-nitropropionic acid-induced behavioral, biochemical, and mitochondrial dysfunction in an animal model of Huntington\u2019s disease. J Med Food 12:591\u2013600. https:\/\/doi.org\/10.1089\/JMF.2008.0028","journal-title":"J Med Food"},{"key":"3604_CR165","doi-asserted-by":"publisher","first-page":"41","DOI":"10.4103\/IJNPND.IJNPND_51_18","volume":"9","author":"M Essa","year":"2019","unstructured":"Essa M, Singh V, Guizani N et al (2019) Phoenix dactylifera L. Fruits date fruit ameliorate oxidative stress in 3-NP intoxicated PC12 cells. Int J Nutr Pharmacol Neurol Dis 9:41. https:\/\/doi.org\/10.4103\/IJNPND.IJNPND_51_18","journal-title":"Int J Nutr Pharmacol Neurol Dis"},{"key":"3604_CR166","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1002\/PTR.3042","volume":"24","author":"GK Shinomol","year":"2010","unstructured":"Shinomol GK, Ravikumar H, Muralidhara (2010) Prophylaxis with Centella asiatica confers protection to prepubertal mice against 3-nitropropionic-acid-induced oxidative stress in brain. Phyther Res 24:885\u2013892. https:\/\/doi.org\/10.1002\/PTR.3042","journal-title":"Phyther Res"},{"key":"3604_CR167","doi-asserted-by":"publisher","unstructured":"Jang M, Lee MJ, Kim CS, Cho IH (2013) Korean red ginseng extract attenuates 3-nitropropionic acid-induced Huntington\u2019s-like symptoms. Evid Based Complement Alternat Med 2013. https:\/\/doi.org\/10.1155\/2013\/237207","DOI":"10.1155\/2013\/237207"},{"key":"3604_CR168","doi-asserted-by":"publisher","unstructured":"Courtes AA, Arantes LP, Barcelos RP et al (2015) Protective effects of aqueous extract of luehea divaricata against behavioral and oxidative changes induced by 3-nitropropionic acid in rats. Evid Based Complement Alternat Med 2015. https:\/\/doi.org\/10.1155\/2015\/723431","DOI":"10.1155\/2015\/723431"},{"key":"3604_CR169","doi-asserted-by":"publisher","unstructured":"Bhangale JO, Acharya NS, Acharya SR (2016) Protective effect of Ficus religiosa (L.) against 3-nitropropionic acid induced Huntington disease. Orient Pharm Exp Med 16(3):165\u2013174. https:\/\/doi.org\/10.1007\/S13596-016-0237-7","DOI":"10.1007\/S13596-016-0237-7"},{"key":"3604_CR170","doi-asserted-by":"publisher","first-page":"764","DOI":"10.3389\/FPHAR.2020.00764\/XML\/NLM","volume":"11","author":"Y Lin","year":"2020","unstructured":"Lin Y, Zhao WR, Shi WT et al (2020) Pharmacological activity, pharmacokinetics, and toxicity of timosaponin AIII, a natural product isolated from Anemarrhena asphodeloides Bunge: a review. Front Pharmacol 11:764. https:\/\/doi.org\/10.3389\/FPHAR.2020.00764\/XML\/NLM","journal-title":"Front Pharmacol"},{"key":"3604_CR171","doi-asserted-by":"publisher","first-page":"1904","DOI":"10.1002\/JNR.22017","volume":"87","author":"J Wu","year":"2009","unstructured":"Wu J, Jeong HK, Bulin SE et al (2009) Ginsenosides protect striatal neurons in a cellular model of Huntington\u2019s disease. J Neurosci Res 87:1904\u20131912. https:\/\/doi.org\/10.1002\/JNR.22017","journal-title":"J Neurosci Res"},{"key":"3604_CR172","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1016\/0076-6879(90)86128-I","volume":"186","author":"W Bors","year":"1990","unstructured":"Bors W, Heller W, Michel C, Saran M (1990) Flavonoids as antioxidants: determination of radical-scavenging efficiencies. Methods Enzymol 186:343\u2013355. https:\/\/doi.org\/10.1016\/0076-6879(90)86128-I","journal-title":"Methods Enzymol"},{"key":"3604_CR173","unstructured":"Narayana KRAJ, Reddy MS, Chaluvadi MR, Krishna DR (2001) Bioflavonoids classification, pharmacological, biochemical effects and therapeutic potential. Indian J Pharmacol 33:2\u201316"},{"key":"3604_CR174","doi-asserted-by":"publisher","first-page":"950","DOI":"10.1093\/jaoac\/83.4.950","volume":"83","author":"RL Prior","year":"2000","unstructured":"Prior RL, Cao G (2000) Analysis of botanicals and dietary supplements for antioxidant capacity: A review. J AOAC Int 83:950\u2013956. https:\/\/doi.org\/10.1093\/jaoac\/83.4.950","journal-title":"J AOAC Int"},{"key":"3604_CR175","doi-asserted-by":"publisher","first-page":"1726","DOI":"10.1136\/BMJ.296.6638.1726","volume":"296","author":"PDC Smith","year":"1988","unstructured":"Smith PDC, Thomas P, Scurr JH, Dormandy JA (1988) Causes of venous ulceration: a new hypothesis. Br Med J (Clin Res Ed) 296:1726\u20131727. https:\/\/doi.org\/10.1136\/BMJ.296.6638.1726","journal-title":"Br Med J (Clin Res Ed)"},{"key":"3604_CR176","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1016\/S0197-4580(02)00075-1","volume":"23","author":"H Schroeter","year":"2002","unstructured":"Schroeter H, Boyd C, Spencer JPE et al (2002) MAPK signaling in neurodegeneration: influences of flavonoids and of nitric oxide. Neurobiol Aging 23:861\u2013880. https:\/\/doi.org\/10.1016\/S0197-4580(02)00075-1","journal-title":"Neurobiol Aging"},{"key":"3604_CR177","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1124\/MOL.65.4.851","volume":"65","author":"G L\u00f3pez-L\u00f3pez","year":"2004","unstructured":"L\u00f3pez-L\u00f3pez G, Moreno L, Cogolludo A et al (2004) Nitric oxide (NO) scavenging and NO protecting effects of quercetin and their biological significance in vascular smooth muscle. Mol Pharmacol 65:851\u2013859. https:\/\/doi.org\/10.1124\/MOL.65.4.851","journal-title":"Mol Pharmacol"},{"key":"3604_CR178","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/J.CTIM.2019.05.017","volume":"45","author":"M Nasiri","year":"2019","unstructured":"Nasiri M, Gheibi Z, Miri A et al (2019) Effects of consuming date fruits (Phoenix dactylifera Linn) on gestation, labor, and delivery: an updated systematic review and meta-analysis of clinical trials. Complement Ther Med 45:71\u201384. https:\/\/doi.org\/10.1016\/J.CTIM.2019.05.017","journal-title":"Complement Ther Med"},{"key":"3604_CR179","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1016\/S0024-3205(00)00999-1","volume":"68","author":"GM Raso","year":"2001","unstructured":"Raso GM, Meli R, Di Carlo G et al (2001) Inhibition of inducible nitric oxide synthase and cyclooxygenase-2 expression by flavonoids in macrophage J774A.1. Life Sci 68:921\u2013931. https:\/\/doi.org\/10.1016\/S0024-3205(00)00999-1","journal-title":"Life Sci"},{"key":"3604_CR180","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1111\/J.1472-8206.2007.00485.X","volume":"21","author":"P Kumar","year":"2007","unstructured":"Kumar P, Padi SSV, Naidu PS, Kumar A (2007) Cyclooxygenase inhibition attenuates 3-nitropropionic acid-induced neurotoxicity in rats: possible antioxidant mechanisms. Fundam Clin Pharmacol 21:297\u2013306. https:\/\/doi.org\/10.1111\/J.1472-8206.2007.00485.X","journal-title":"Fundam Clin Pharmacol"},{"key":"3604_CR181","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1016\/S0891-5849(00)00498-6","volume":"30","author":"K Ishige","year":"2001","unstructured":"Ishige K, Schubert D, Sagara Y (2001) Flavonoids protect neuronal cells from oxidative stress by three distinct mechanisms. Free Radic Biol Med 30:433\u2013446. https:\/\/doi.org\/10.1016\/S0891-5849(00)00498-6","journal-title":"Free Radic Biol Med"},{"key":"3604_CR182","first-page":"160","volume":"4","author":"A Jayaprakash","year":"2015","unstructured":"Jayaprakash A, Sangeetha R (2015) Phytochemical screening of Punica granatum Linn. peel extracts. J Acad Ind Res 4:160","journal-title":"J Acad Ind Res"},{"key":"3604_CR183","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/J.BBR.2009.08.028","volume":"206","author":"P Kumar","year":"2010","unstructured":"Kumar P, Kumar A (2010) Protective effect of hesperidin and naringin against 3-nitropropionic acid induced Huntington\u2019s like symptoms in rats: possible role of nitric oxide. Behav Brain Res 206:38\u201346. https:\/\/doi.org\/10.1016\/J.BBR.2009.08.028","journal-title":"Behav Brain Res"},{"key":"3604_CR184","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1111\/J.1742-7843.2010.00537.X","volume":"107","author":"P Kumar","year":"2010","unstructured":"Kumar P, Kalonia H, Kumar A (2010) Protective effect of sesamol against 3-nitropropionic acid-induced cognitive dysfunction and altered glutathione redox balance in rats. Basic Clin Pharmacol Toxicol 107:577\u2013582. https:\/\/doi.org\/10.1111\/J.1742-7843.2010.00537.X","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"3604_CR185","doi-asserted-by":"publisher","first-page":"1","DOI":"10.18502\/PBR.V4I2.214","volume":"4","author":"PK Verma","year":"2018","unstructured":"Verma PK, Raina R, Agarwal S, Kaur H (2018) Phytochemical ingredients and Pharmacological potential of Calendula officinalis Linn. Pharm Biomed Res 4:1\u201317. https:\/\/doi.org\/10.18502\/PBR.V4I2.214","journal-title":"Pharm Biomed Res"},{"key":"3604_CR186","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1111\/J.1471-4159.2009.06331.X","volume":"111","author":"R Lagoa","year":"2009","unstructured":"Lagoa R, Lopez-Sanchez C, Samhan-Arias AK et al (2009) Kaempferol protects against rat striatal degeneration induced by 3-nitropropionic acid. J Neurochem 111:473\u2013487. https:\/\/doi.org\/10.1111\/J.1471-4159.2009.06331.X","journal-title":"J Neurochem"},{"key":"3604_CR187","doi-asserted-by":"publisher","first-page":"1930","DOI":"10.1002\/PTR.7424","volume":"36","author":"K Nagpal","year":"2022","unstructured":"Nagpal K, Garg M, Arora D et al (2022) An extensive review on phytochemistry and pharmacological activities of Indian medicinal plant Celastrus paniculatus Willd. Phyther Res 36:1930\u20131951. https:\/\/doi.org\/10.1002\/PTR.7424","journal-title":"Phyther Res"},{"key":"3604_CR188","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/J.CCCN.2004.12.009","volume":"355","author":"D Sankar","year":"2005","unstructured":"Sankar D, Sambandam G, Ramakrishna Rao M, Pugalendi KV (2005) Modulation of blood pressure, lipid profiles and redox status in hypertensive patients taking different edible oils. Clin Chim Acta 355:97\u2013104. https:\/\/doi.org\/10.1016\/J.CCCN.2004.12.009","journal-title":"Clin Chim Acta"},{"key":"3604_CR189","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/S2221-1691(14)60240-9","volume":"4","author":"P Agarwal","year":"2014","unstructured":"Agarwal P, Sharma B, Fatima A, Jain SK (2014) An update on Ayurvedic herb Convolvulus pluricaulis Choisy. Asian Pac J Trop Biomed 4:245\u2013252. https:\/\/doi.org\/10.1016\/S2221-1691(14)60240-9","journal-title":"Asian Pac J Trop Biomed"},{"key":"3604_CR190","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1016\/S0271-5317(99)00025-1","volume":"19","author":"NH Baba","year":"1999","unstructured":"Baba NH, Antoniades K, Habbal Z (1999) Effects of dietary canola, olive, and linolenic acid enriched olive oils on plasma lipids, lipid peroxidation and lipoprotein lipase activity in rats. Nutr Res 19:601\u2013612. https:\/\/doi.org\/10.1016\/S0271-5317(99)00025-1","journal-title":"Nutr Res"},{"key":"3604_CR191","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1006\/PHRS.2002.0992","volume":"45","author":"GJ Kapadia","year":"2002","unstructured":"Kapadia GJ, Azuine MA, Tokuda H et al (2002) Chemopreventive effect of resveratrol, sesamol, sesame oil and sunflower oil in the Epstein-Barr virus early antigen activation assay and the mouse skin two-stage carcinogenesis. Pharmacol Res 45:499\u2013505. https:\/\/doi.org\/10.1006\/PHRS.2002.0992","journal-title":"Pharmacol Res"},{"key":"3604_CR192","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1080\/10286020902862194","volume":"11","author":"P Kumar","year":"2009","unstructured":"Kumar P, Kalonia H, Kumar A (2009) Sesamol attenuate 3-nitropropionic acid-induced Huntington-like behavioral, biochemical, and cellular alterations in rats. J Asian Nat Prod Res 11:439\u2013450. https:\/\/doi.org\/10.1080\/10286020902862194","journal-title":"J Asian Nat Prod Res"},{"key":"3604_CR193","doi-asserted-by":"publisher","first-page":"411","DOI":"10.3390\/PLANTS9040411","volume":"9","author":"PS Saha","year":"2020","unstructured":"Saha PS, Sarkar S, Jeyasri R et al (2020) In vitro propagation, phytochemical and neuropharmacological profiles of Bacopa monnieri (L.) Wettst.: a review. Plants 9:411. https:\/\/doi.org\/10.3390\/PLANTS9040411","journal-title":"Plants"},{"key":"3604_CR194","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/J.JEP.2014.02.013","volume":"153","author":"Y Wang","year":"2014","unstructured":"Wang Y, Dan Y, Yang D et al (2014) The genus Anemarrhena Bunge: a review on ethnopharmacology, phytochemistry and pharmacology. J Ethnopharmacol 153:42\u201360. https:\/\/doi.org\/10.1016\/J.JEP.2014.02.013","journal-title":"J Ethnopharmacol"},{"key":"3604_CR195","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/J.TOX.2008.11.012","volume":"256","author":"J Renugadevi","year":"2009","unstructured":"Renugadevi J, Prabu SM (2009) Naringenin protects against cadmium-induced oxidative renal dysfunction in rats. Toxicology 256:128\u2013134. https:\/\/doi.org\/10.1016\/J.TOX.2008.11.012","journal-title":"Toxicology"},{"key":"3604_CR196","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1097\/shk.0b013e31804d4474","volume":"28","author":"D-Z Hsu","year":"2007","unstructured":"Hsu D-Z, Chien S-P, Chen K-T, Liu M-Y (2007) The effect of sesamol on systemic oxidative stress and hepatic dysfunction in acutely iron-intoxicated mice. Shock 28:596\u2013601. https:\/\/doi.org\/10.1097\/shk.0b013e31804d4474","journal-title":"Shock"},{"key":"3604_CR197","doi-asserted-by":"publisher","unstructured":"Jadiya P, Khan A, Sammi SR, Kaur S, Mir SS, Nazir A (2011) Anti-Parkinsonian effects of Bacopa monnieri: insights from transgenic and pharmacological Caenorhabditis elegans models of Parkinson\u2019s disease. Biochem Biophys Res Commun 413:605\u2013610. https:\/\/doi.org\/10.1016\/j.bbrc.2011.09.010","DOI":"10.1016\/j.bbrc.2011.09.010"},{"key":"3604_CR198","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1016\/J.JCHROMB.2017.06.032","volume":"1060","author":"D Ji","year":"2017","unstructured":"Ji D, Huang Zy, Fei Ch et al (2017) Comprehensive profiling and characterization of chemical constituents of rhizome of Anemarrhena asphodeloides Bge. J Chromatogr B Analyt Technol Biomed Life Sci 1060:355\u2013366. https:\/\/doi.org\/10.1016\/J.JCHROMB.2017.06.032","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"key":"3604_CR199","doi-asserted-by":"publisher","unstructured":"Parvin S, Easmin D, Sheikh A et al (2015) Nutritional analysis of date fruits (Phoenix dactylifera L.) in perspective of Bangladesh. article. ajlifesci.org 3:274\u2013278. https:\/\/doi.org\/10.11648\/j.ajls.20150304.14","DOI":"10.11648\/j.ajls.20150304.14"},{"key":"3604_CR200","doi-asserted-by":"publisher","unstructured":"Al Alawi R, Alhamdani MSS, Hoheisel JD, Baqi Y (2020) Antifibrotic and tumor microenvironment modulating effect of date palm fruit (Phoenix dactylifera L.) extracts in pancreatic cancer. Biomed Pharmacother 121. https:\/\/doi.org\/10.1016\/J.BIOPHA.2019.109522","DOI":"10.1016\/J.BIOPHA.2019.109522"},{"key":"3604_CR201","doi-asserted-by":"publisher","first-page":"554","DOI":"10.3389\/FPLS.2020.00554\/XML\/NLM","volume":"11","author":"KA Aliferis","year":"2020","unstructured":"Aliferis KA, Bernard-Perron D (2020) Cannabinomics: application of metabolomics in Cannabis (Cannabis sativa L.) research and development. Front Plant Sci 11:554. https:\/\/doi.org\/10.3389\/FPLS.2020.00554\/XML\/NLM","journal-title":"Front Plant Sci"},{"key":"3604_CR202","doi-asserted-by":"publisher","unstructured":"Ayaz Ali B SY, Sameer SD, Patel A, et al Pharmacokinetic drug food interaction study of nateglinide and pomegranate fruit juice. Iran J Diabetes Obes 12. https:\/\/doi.org\/10.18502\/ijdo.v12i4.5181","DOI":"10.18502\/ijdo.v12i4.5181"},{"key":"3604_CR203","doi-asserted-by":"publisher","unstructured":"BenSaad LA, Kim KH, Quah CC et al (2017) Anti-inflammatory potential of ellagic acid, gallic acid and punicalagin A&B isolated from Punica granatum. BMC Complement Alternat Med 17. https:\/\/doi.org\/10.1186\/S12906-017-1555-0","DOI":"10.1186\/S12906-017-1555-0"},{"key":"3604_CR204","doi-asserted-by":"publisher","first-page":"455","DOI":"10.4314\/tjpr.v8i5.48090","volume":"8","author":"BP Muley","year":"2009","unstructured":"Muley BP, Khadabadi SS, Banarase NB (2009) Phytochemical constituents and pharmacological activities of Calendula officinalis Linn (Asteraceae): a review. Trop J Pharm Res 8:455\u2013465. https:\/\/doi.org\/10.4314\/tjpr.v8i5.48090","journal-title":"Trop J Pharm Res"},{"key":"3604_CR205","doi-asserted-by":"publisher","unstructured":"Lim XY, Tan TYC, Rosli SHM et al (2021) Cannabis sativa subsp. sativa\u2019s pharmacological properties and health effects: a scoping review of current evidence. PLoS One 16. https:\/\/doi.org\/10.1371\/JOURNAL.PONE.0245471","DOI":"10.1371\/JOURNAL.PONE.0245471"},{"key":"3604_CR206","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1016\/J.JEP.2016.06.057","volume":"189","author":"HD Zhan","year":"2016","unstructured":"Zhan HD, Zhou HY, Sui YP et al (2016) The rhizome of Gastrodia elata Blume \u2013 an ethnopharmacological review. J Ethnopharmacol 189:361\u2013385. https:\/\/doi.org\/10.1016\/J.JEP.2016.06.057","journal-title":"J Ethnopharmacol"},{"key":"3604_CR207","doi-asserted-by":"publisher","first-page":"1448","DOI":"10.3109\/13880209.2014.984856","volume":"53","author":"J Malik","year":"2015","unstructured":"Malik J, Choudhary S, Kumar P (2015) Protective effect of Convolvulus pluricaulis standardized extract and its fractions against 3-nitropropionic acid-induced neurotoxicity in rats. Pharm Biol 53:1448\u20131457. https:\/\/doi.org\/10.3109\/13880209.2014.984856","journal-title":"Pharm Biol"},{"key":"3604_CR208","doi-asserted-by":"publisher","unstructured":"Godkar PB, Gordon RK, Ravindran A, Doctor BP (2004) Celastrus paniculatus seed water soluble extracts protect against glutamate toxicity in neuronal cultures from rat forebrain. J Ethnopharmacol 93:213\u2013219. https:\/\/doi.org\/10.1016\/J.JEP.2004.03.051","DOI":"10.1016\/J.JEP.2004.03.051"},{"issue":"8","key":"3604_CR209","doi-asserted-by":"publisher","first-page":"1593","DOI":"10.1142\/S0192415X15500901","volume":"43","author":"LY Wu","year":"2015","unstructured":"Wu LY, Chen WC, Tsai FS, Tsai CC, Wu CR, Lin LW (2015) p-Hydroxybenzyl alcohol, an active phenolic Ingredient of Gastrodia elata, reverses the cycloheximide-induced memory deficit by activating the adrenal gland in rats. Am J Chin Med 43(8):1593\u2013604. https:\/\/doi.org\/10.1142\/S0192415X15500901","journal-title":"Am J Chin Med"},{"key":"3604_CR210","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.1016\/J.BCP.2012.07.018","volume":"84","author":"M Tillhon","year":"2012","unstructured":"Tillhon M, Guam\u00e1n Ortiz LM, Lombardi P, Scovassi AI (2012) Berberine: new perspectives for old remedies. Biochem Pharmacol 84:1260\u20131267. https:\/\/doi.org\/10.1016\/J.BCP.2012.07.018","journal-title":"Biochem Pharmacol"},{"key":"3604_CR211","doi-asserted-by":"publisher","unstructured":"Chen C-C, Hung T-H, Lee CY, Wang L-F, Wu C-H, Ke C-H, Chen S-F et al (2014) Berberine protects against neuronal damage via suppression of glia-mediated inflammation in traumatic brain injury. PLoS ONE\u00a09:e115694. https:\/\/doi.org\/10.1371\/journal.pone.0115694","DOI":"10.1371\/journal.pone.0115694"},{"key":"3604_CR212","doi-asserted-by":"publisher","first-page":"410","DOI":"10.4103\/0973-1296.153097","volume":"11","author":"SC Phulara","year":"2015","unstructured":"Phulara SC, Shukla V, Tiwari S, Pandey R (2015) Bacopa monnieri promotes longevity in Caenorhabditis elegans under stress conditions. Pharmacogn Mag 11:410\u2013416. https:\/\/doi.org\/10.4103\/0973-1296.153097","journal-title":"Pharmacogn Mag"},{"key":"3604_CR213","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/J.BIOPHA.2015.12.013","volume":"78","author":"A Chowdhury","year":"2016","unstructured":"Chowdhury A, Sarkar J, Chakraborti T et al (2016) Protective role of epigallocatechin-3-gallate in health and disease: a perspective. Biomed Pharmacother 78:50\u201359. https:\/\/doi.org\/10.1016\/J.BIOPHA.2015.12.013","journal-title":"Biomed Pharmacother"},{"key":"3604_CR214","doi-asserted-by":"publisher","first-page":"9931","DOI":"10.3390\/NU7125507","volume":"7","author":"JD Kean","year":"2015","unstructured":"Kean JD, Kaufman J, Lomas J et al (2015) A randomized controlled trial investigating the effects of a special extract of Bacopa monnieri (CDRI 08) on hyperactivity and inattention in male children and adolescents: BACHI study protocol (ANZCTRN12612000827831). Nutrients 7:9931\u20139945. https:\/\/doi.org\/10.3390\/NU7125507","journal-title":"Nutrients"},{"key":"3604_CR215","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1002\/PTR.5029","volume":"28","author":"S Benson","year":"2014","unstructured":"Benson S, Downey LA, Stough C et al (2014) An acute, double-blind, placebo-controlled cross-over study of 320 mg and 640 mg doses of Bacopa monnieri (CDRI 08) on multitasking stress reactivity and mood. Phytother Res 28:551\u2013559. https:\/\/doi.org\/10.1002\/PTR.5029","journal-title":"Phytother Res"},{"key":"3604_CR216","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1002\/PTR.4864","volume":"27","author":"LA Downey","year":"2013","unstructured":"Downey LA, Kean J, Nemeh F et al (2013) An acute, double-blind, placebo-controlled crossover study of 320 mg and 640 mg doses of a special extract of Bacopa monnieri (CDRI 08) on sustained cognitive performance. Phytother Res 27:1407\u20131413. https:\/\/doi.org\/10.1002\/PTR.4864","journal-title":"Phytother Res"},{"key":"3604_CR217","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1016\/J.BIOCEL.2005.08.020","volume":"38","author":"R Hardeland","year":"2006","unstructured":"Hardeland R, Pandi-Perumal SR, Cardinali DP (2006) Melatonin. Int J Biochem Cell Biol 38:313\u2013316. https:\/\/doi.org\/10.1016\/J.BIOCEL.2005.08.020","journal-title":"Int J Biochem Cell Biol"},{"key":"3604_CR218","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/J.SMRV.2004.05.002","volume":"9","author":"J Arendt","year":"2005","unstructured":"Arendt J, Skene DJ (2005) Melatonin as a chronobiotic. Sleep Med Rev 9:25\u201339. https:\/\/doi.org\/10.1016\/J.SMRV.2004.05.002","journal-title":"Sleep Med Rev"},{"key":"3604_CR219","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/J.JEP.2009.09.056","volume":"127","author":"N Uabundit","year":"2010","unstructured":"Uabundit N, Wattanathorn J, Mucimapura S, Ingkaninan K (2010) Cognitive enhancement and neuroprotective effects of Bacopa monnieri in Alzheimer\u2019s disease model. J Ethnopharmacol 127:26\u201331. https:\/\/doi.org\/10.1016\/J.JEP.2009.09.056","journal-title":"J Ethnopharmacol"},{"key":"3604_CR220","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1016\/J.PHYMED.2010.08.005","volume":"18","author":"GK Shinomol","year":"2011","unstructured":"Shinomol GK, Muralidhara (2011) Bacopa monnieri modulates endogenous cytoplasmic and mitochondrial oxidative markers in prepubertal mice brain. Phytomedicine 18:317\u2013326. https:\/\/doi.org\/10.1016\/J.PHYMED.2010.08.005","journal-title":"Phytomedicine"},{"key":"3604_CR221","doi-asserted-by":"publisher","first-page":"637","DOI":"10.3390\/NU5030637","volume":"5","author":"MA Alam","year":"2013","unstructured":"Alam MA, Kauter K, Brown L (2013) Naringin improves diet-induced cardiovascular dysfunction and obesity in high carbohydrate, high fat diet-fed rats. Nutrients 5:637\u2013650. https:\/\/doi.org\/10.3390\/NU5030637","journal-title":"Nutrients"},{"key":"3604_CR222","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1139\/Y2012-030","volume":"90","author":"GK Shinomol","year":"2012","unstructured":"Shinomol GK, Bharath MMB, Muralidhara (2012) Pretreatment with Bacopa monnieri extract offsets 3-nitropropionic acid induced mitochondrial oxidative stress and dysfunctions in the striatum of prepubertal mouse brain. Can J Physiol Pharmacol 90:595\u2013606. https:\/\/doi.org\/10.1139\/Y2012-030","journal-title":"Can J Physiol Pharmacol"},{"key":"3604_CR223","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1007\/S12640-011-9303-6","volume":"22","author":"GK Shinomol","year":"2012","unstructured":"Shinomol GK, Srinivas Bharath MM, Muralidhara (2012) Neuromodulatory propensity of Bacopa monnieri leaf extract against 3-nitropropionic acid-induced oxidative stress: in vitro and in vivo evidences. Neurotox Res 22:102\u2013114. https:\/\/doi.org\/10.1007\/S12640-011-9303-6","journal-title":"Neurotox Res"},{"key":"3604_CR224","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1021\/NP50008A001","volume":"43","author":"CE Turner","year":"1980","unstructured":"Turner CE, Elsohly MA, Boeren EG (1980) Constituents of Cannabis sativa L. XVII. A review of the natural constituents. J Nat Prod 43:169\u2013234. https:\/\/doi.org\/10.1021\/NP50008A001","journal-title":"J Nat Prod"},{"key":"3604_CR225","doi-asserted-by":"publisher","unstructured":"Sharma P, Kumar V, Guleria P (2019) Naringin: biosynthesis and pharmaceutical applications. Indian J Pharm Sci 81:988\u2013999. https:\/\/doi.org\/10.36468\/PHARMACEUTICAL-SCIENCES.596","DOI":"10.36468\/PHARMACEUTICAL-SCIENCES.596"},{"key":"3604_CR226","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1177\/0269881114550355","volume":"28","author":"MHN Chagas","year":"2014","unstructured":"Chagas MHN, Zuardi AW, Tumas V et al (2014) Effects of cannabidiol in the treatment of patients with Parkinson\u2019s disease: an exploratory double-blind trial. J Psychopharmacol 28:1088\u20131092. https:\/\/doi.org\/10.1177\/0269881114550355","journal-title":"J Psychopharmacol"},{"key":"3604_CR227","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1111\/JCPT.12179","volume":"39","author":"MHN Chagas","year":"2014","unstructured":"Chagas MHN, Eckeli AL, Zuardi AW et al (2014) Cannabidiol can improve complex sleep-related behaviours associated with rapid eye movement sleep behaviour disorder in Parkinson\u2019s disease patients: a case series. J Clin Pharm Ther 39:564\u2013566. https:\/\/doi.org\/10.1111\/JCPT.12179","journal-title":"J Clin Pharm Ther"},{"key":"3604_CR228","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1002\/CPT.117","volume":"97","author":"AIA Ahmed","year":"2015","unstructured":"Ahmed AIA, Van Der Marck MA, Van Den Elsen GAH, Olde Rikkert MGM (2015) Cannabinoids in late-onset Alzheimer\u2019s disease. Clin Pharmacol Ther 97:597\u2013606. https:\/\/doi.org\/10.1002\/CPT.117","journal-title":"Clin Pharmacol Ther"},{"key":"3604_CR229","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.1002\/JNR.22682","volume":"89","author":"O Sagredo","year":"2011","unstructured":"Sagredo O, Pazos MR, Satta V et al (2011) Neuroprotective effects of phytocannabinoid-based medicines in experimental models of Huntington\u2019s disease. J Neurosci Res 89:1509\u20131518. https:\/\/doi.org\/10.1002\/JNR.22682","journal-title":"J Neurosci Res"},{"key":"3604_CR230","doi-asserted-by":"publisher","first-page":"2666","DOI":"10.3390\/MOLECULES26092666","volume":"26","author":"B Stachowiak","year":"2021","unstructured":"Stachowiak B, Szulc P (2021) Astaxanthin for the food industry. Molecules 26:2666. https:\/\/doi.org\/10.3390\/MOLECULES26092666","journal-title":"Molecules"},{"key":"3604_CR231","doi-asserted-by":"publisher","first-page":"128","DOI":"10.3390\/MD12010128","volume":"12","author":"RR Ambati","year":"2014","unstructured":"Ambati RR, Moi PS, Ravi S, Aswathanarayana RG (2014) Astaxanthin: sources, extraction, stability, biological activities and its commercial applications\u2013a review. Mar Drugs 12:128\u2013152. https:\/\/doi.org\/10.3390\/MD12010128","journal-title":"Mar Drugs"},{"key":"3604_CR232","doi-asserted-by":"publisher","unstructured":"Galasso C, Orefice I, Pellone P et al (2018) On the neuroprotective role of astaxanthin: new perspectives? Mar Drugs 16. https:\/\/doi.org\/10.3390\/MD16080247","DOI":"10.3390\/MD16080247"},{"key":"3604_CR233","doi-asserted-by":"publisher","first-page":"24126","DOI":"10.1021\/ACSAMI.7B06510\/SUPPL_FILE\/AM7B06510_LIVESLIDES.MP4","volume":"9","author":"K Debnath","year":"2017","unstructured":"Debnath K, Pradhan N, Singh BK et al (2017) Poly(trehalose) nanoparticles prevent amyloid aggregation and suppress polyglutamine aggregation in a Huntington\u2019s disease model mouse. ACS Appl Mater Interfaces 9:24126\u201324139. https:\/\/doi.org\/10.1021\/ACSAMI.7B06510\/SUPPL_FILE\/AM7B06510_LIVESLIDES.MP4","journal-title":"ACS Appl Mater Interfaces"},{"key":"3604_CR234","doi-asserted-by":"publisher","unstructured":"Sztretye M, Dienes B, G\u00f6nczi M et al (2019) Astaxanthin: a potential mitochondrial-targeted antioxidant treatment in diseases and with aging. Oxid Med Cell Longev 2019. https:\/\/doi.org\/10.1155\/2019\/3849692","DOI":"10.1155\/2019\/3849692"},{"key":"3604_CR235","doi-asserted-by":"publisher","first-page":"5750","DOI":"10.3390\/MD13095750","volume":"13","author":"H Wu","year":"2015","unstructured":"Wu H, Niu H, Shao A et al (2015) Astaxanthin as a potential neuroprotective agent for neurological diseases. Mar Drugs 13:5750\u20135766. https:\/\/doi.org\/10.3390\/MD13095750","journal-title":"Mar Drugs"},{"key":"3604_CR236","doi-asserted-by":"publisher","unstructured":"Popova MP Caffeic acid phenethyl ester (CAPE)-Natural sources, analytical procedures and synthetic approaches. https:\/\/doi.org\/10.7546\/CRABS.2018.09.01","DOI":"10.7546\/CRABS.2018.09.01"},{"key":"3604_CR237","doi-asserted-by":"publisher","unstructured":"Manochkumar J, Doss CGP, El-Seedi HR et al (2021) The neuroprotective potential of carotenoids in vitro and in vivo. Phytomedicine 91. https:\/\/doi.org\/10.1016\/J.PHYMED.2021.153676","DOI":"10.1016\/J.PHYMED.2021.153676"},{"key":"3604_CR238","doi-asserted-by":"publisher","unstructured":"Murtaza G, Karim S, Akram MR et al (2014) Caffeic acid phenethyl ester and therapeutic potentials. Biomed Res Int 2014. https:\/\/doi.org\/10.1155\/2014\/145342","DOI":"10.1155\/2014\/145342"},{"key":"3604_CR239","doi-asserted-by":"publisher","unstructured":"Wan T, Wang Z, Luo Y et al (2019) FA-97, a new synthetic caffeic acid phenethyl ester derivative, protects against oxidative stress-mediated neuronal cell apoptosis and scopolamine-induced cognitive impairment by activating Nrf2\/HO-1 signaling. Oxid Med Cell Longev 2019. https:\/\/doi.org\/10.1155\/2019\/8239642","DOI":"10.1155\/2019\/8239642"},{"key":"3604_CR240","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/J.JEP.2012.09.005","volume":"144","author":"J Zhang","year":"2012","unstructured":"Zhang J, Li CY, Xu MJ et al (2012) Oral bioavailability and gender-related pharmacokinetics of celastrol following administration of pure celastrol and its related tablets in rats. J Ethnopharmacol 144:195\u2013200. https:\/\/doi.org\/10.1016\/J.JEP.2012.09.005","journal-title":"J Ethnopharmacol"},{"key":"3604_CR241","doi-asserted-by":"publisher","first-page":"97","DOI":"10.2174\/187152108783954632","volume":"7","author":"NH Lee","year":"2008","unstructured":"Lee NH, Ho JW (2008) Celastrol and terpenes as anti-infective agents. Antiinfect Agents Med Chem 7:97\u2013100. https:\/\/doi.org\/10.2174\/187152108783954632","journal-title":"Antiinfect Agents Med Chem"},{"key":"3604_CR242","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1111\/j.1471-4159.2005.03253.x","volume":"94","author":"C Cleren","year":"2005","unstructured":"Cleren C, Calingasan NY, Chen J, Beal MF (2005) Celastrol protects against MPTP- and 3-nitropropionic acid-induced neurotoxicity. J Neurochem 94:995\u20131004. https:\/\/doi.org\/10.1111\/j.1471-4159.2005.03253.x","journal-title":"J Neurochem"},{"key":"3604_CR243","doi-asserted-by":"publisher","first-page":"1401","DOI":"10.2174\/1570159X19666210608165509","volume":"19","author":"NP Kulkarni","year":"2021","unstructured":"Kulkarni NP, Vaidya B, Narula AS, Sharma SS (2021) Neuroprotective potential of caffeic acid phenethyl ester (CAPE) in CNS disorders: mechanistic and therapeutic insights. Curr Neuropharmacol 19:1401\u20131415. https:\/\/doi.org\/10.2174\/1570159X19666210608165509","journal-title":"Curr Neuropharmacol"},{"key":"3604_CR244","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1379\/CSC-269.1","volume":"12","author":"AM Chow","year":"2007","unstructured":"Chow AM, Brown IR (2007) Induction of heat shock proteins in differentiated human and rodent neurons by celastrol. Cell Stress Chaperones 12:237\u2013244. https:\/\/doi.org\/10.1379\/CSC-269.1","journal-title":"Cell Stress Chaperones"},{"key":"3604_CR245","doi-asserted-by":"publisher","unstructured":"Cleren C, Calingasan NY, Chen J, Beal MF (2005) Celastrol protects against MPTP- and 3-nitropropionic acid-induced neurotoxicity. 94:995\u20131004. https:\/\/doi.org\/10.1111\/J.1471-4159.2005.03253.X","DOI":"10.1111\/J.1471-4159.2005.03253.X"},{"key":"3604_CR246","doi-asserted-by":"publisher","unstructured":"Duennwald ML (2015) Cellular stress responses in protein misfolding diseases. Futur Sci OA 1. https:\/\/doi.org\/10.4155\/FSO.15.42","DOI":"10.4155\/FSO.15.42"},{"key":"3604_CR247","doi-asserted-by":"crossref","unstructured":"Zhang YQ, Sarge KD (2007) Celastrol inhibits polyglutamine aggregation and toxicity though induction of the heat shock response. 85:1421\u20131428","DOI":"10.1007\/s00109-007-0251-9"},{"key":"3604_CR248","doi-asserted-by":"publisher","first-page":"7472","DOI":"10.1074\/JBC.RA118.006506","volume":"294","author":"C Zhang","year":"2019","unstructured":"Zhang C, Wang R, Liu Z et al (2019) The plant triterpenoid celastrol blocks PINK1-dependent mitophagy by disrupting PINK1\u2019s association with the mitochondrial protein TOM20. J Biol Chem 294:7472\u20137487. https:\/\/doi.org\/10.1074\/JBC.RA118.006506","journal-title":"J Biol Chem"},{"key":"3604_CR249","doi-asserted-by":"publisher","unstructured":"Lyu M, Yang C (2021) Neuroprotective effects of celastrol in neurodegenerative diseases-unscramble its major mechanisms of action and targets Platelet-tumor communication View project TCM Attenuates TMAO-Induced Thrombosis via Remodeling of the Gut Microbiota View project. https:\/\/doi.org\/10.14336\/AD.2021.1115","DOI":"10.14336\/AD.2021.1115"},{"key":"3604_CR250","doi-asserted-by":"publisher","first-page":"2020","DOI":"10.5530\/srp.2020.3.60","volume":"11","author":"MK Oglah","year":"2020","unstructured":"Oglah MK, Fakri Mustafa Y, Kahtan Bashir M et al (2020) Curcumin and its derivatives: a review of their biological activities. Syst Rev Pharm 11:2020. https:\/\/doi.org\/10.5530\/srp.2020.3.60","journal-title":"Syst Rev Pharm"},{"key":"3604_CR251","doi-asserted-by":"publisher","unstructured":"Egan ME (2004) Curcumin, a major constituent of turmeric, corrects cystic fibrosis defects. Science 304:600\u2013602. https:\/\/doi.org\/10.1126\/science.1093941","DOI":"10.1126\/science.1093941"},{"key":"3604_CR252","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/J.THROMRES.2010.11.007","volume":"127","author":"P Prakash","year":"2011","unstructured":"Prakash P, Misra A, Surin WR et al (2011) Anti-platelet effects of Curcuma oil in experimental models of myocardial ischemia-reperfusion and thrombosis. Thromb Res 127:111\u2013118. https:\/\/doi.org\/10.1016\/J.THROMRES.2010.11.007","journal-title":"Thromb Res"},{"key":"3604_CR253","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1016\/J.FREERADBIOMED.2007.05.009","volume":"43","author":"SK Sandur","year":"2007","unstructured":"Sandur SK, Ichikawa H, Pandey MK et al (2007) Role of pro-oxidants and antioxidants in the anti-inflammatory and apoptotic effects of curcumin (diferuloylmethane). Free Radic Biol Med 43:568\u2013580. https:\/\/doi.org\/10.1016\/J.FREERADBIOMED.2007.05.009","journal-title":"Free Radic Biol Med"},{"key":"3604_CR254","doi-asserted-by":"publisher","first-page":"330","DOI":"10.5001\/OMJ.2014.89","volume":"29","author":"R Afshariani","year":"2014","unstructured":"Afshariani R, Farhadi P, Ghaffarpasand F, Roozbeh J (2014) Effectiveness of topical curcumin for treatment of mastitis in breastfeeding women: a randomized, double-blind, placebo-controlled clinical trial. Oman Med J 29:330\u2013334. https:\/\/doi.org\/10.5001\/OMJ.2014.89","journal-title":"Oman Med J"},{"key":"3604_CR255","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1080\/14737175.2021.1923479","volume":"21","author":"M Talebi","year":"2021","unstructured":"Talebi M, Kakouri E, Talebi M et al (2021) Nutraceuticals-based therapeutic approach: recent advances to combat pathogenesis of Alzheimer\u2019s disease. Expert Rev Neurother 21:625\u2013642. https:\/\/doi.org\/10.1080\/14737175.2021.1923479","journal-title":"Expert Rev Neurother"},{"key":"3604_CR256","doi-asserted-by":"publisher","unstructured":"Verma M, Sharma A, Naidu S et al (2012) Curcumin prevents formation of polyglutamine aggregates by inhibiting Vps36, a component of the ESCRT-II complex. PLoS One 7. https:\/\/doi.org\/10.1371\/JOURNAL.PONE.0042923","DOI":"10.1371\/JOURNAL.PONE.0042923"},{"key":"3604_CR257","doi-asserted-by":"publisher","unstructured":"Elifani F, Amico E, Pepe G, Capocci L, Castaldo S, Rosa P, Montano E, Pollice A (2019) Curcumin dietary supplementation ameliorates disease phenotype in an animal model of Huntington\u2019s disease. Hum Mol Genet. https:\/\/doi.org\/10.1093\/hmg\/ddz247","DOI":"10.1093\/hmg\/ddz247"},{"key":"3604_CR258","doi-asserted-by":"publisher","first-page":"A93","DOI":"10.1136\/JNNP-2016-314597.264","volume":"87","author":"F Elifani","year":"2016","unstructured":"Elifani F, Crispi S, Filosa S et al (2016) L9 Curcumin: a natural compound to counteract the pathology of huntington\u2019s disease? J Neurol Neurosurg Psychiatry 87:A93\u2013A93. https:\/\/doi.org\/10.1136\/JNNP-2016-314597.264","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"Suppl 2","key":"3604_CR259","doi-asserted-by":"publisher","first-page":"S116","DOI":"10.4103\/0973-1296.182168","volume":"12","author":"DK Khatri","year":"2016","unstructured":"Khatri DK, Juvekar AR (2016) Kinetics of inhibition of monoamine oxidase using curcumin and ellagic acid. Pharmacogn Mag 12(Suppl 2):S116\u201320. https:\/\/doi.org\/10.4103\/0973-1296.182168","journal-title":"Pharmacogn Mag"},{"key":"3604_CR260","doi-asserted-by":"publisher","first-page":"1758","DOI":"10.1007\/S11064-015-1658-2","volume":"40","author":"S Singh","year":"2015","unstructured":"Singh S, Jamwal S, Kumar P (2015) Piperine enhances the protective effect of curcumin against 3-NP induced neurotoxicity: possible neurotransmitters modulation mechanism. Neurochem Res 40:1758\u20131766. https:\/\/doi.org\/10.1007\/S11064-015-1658-2","journal-title":"Neurochem Res"},{"key":"3604_CR261","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/J.JEP.2007.05.030","volume":"113","author":"X Ma","year":"2007","unstructured":"Ma X, Tan C, Zhu D et al (2007) Huperzine A from Huperzia species\u2014an ethnopharmacolgical review. J Ethnopharmacol 113:15\u201334. https:\/\/doi.org\/10.1016\/J.JEP.2007.05.030","journal-title":"J Ethnopharmacol"},{"key":"3604_CR262","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/J.FCT.2014.08.020","volume":"74","author":"OJF Banji","year":"2014","unstructured":"Banji OJF, Banji D, Ch K (2014) Curcumin and hesperidin improve cognition by suppressing mitochondrial dysfunction and apoptosis induced by D-galactose in rat brain. Food Chem Toxicol 74:51\u201359. https:\/\/doi.org\/10.1016\/J.FCT.2014.08.020","journal-title":"Food Chem Toxicol"},{"key":"3604_CR263","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1159\/000336427","volume":"11","author":"M Ratia","year":"2013","unstructured":"Ratia M, Gim\u00e9nez-Llort L, Camps P et al (2013) Huprine X and huperzine A improve cognition and regulate some neurochemical processes related with Alzheimer\u2019s disease in triple transgenic mice (3xTg-AD). Neurodegener Dis 11:129\u2013140. https:\/\/doi.org\/10.1159\/000336427","journal-title":"Neurodegener Dis"},{"key":"3604_CR264","doi-asserted-by":"publisher","unstructured":"Qian ZM, Ke Y (2014) Huperzine A: is it an effective disease-modifying drug for Alzheimer\u2019s disease? Front Aging Neurosci 6. https:\/\/doi.org\/10.3389\/FNAGI.2014.00216","DOI":"10.3389\/FNAGI.2014.00216"},{"key":"3604_CR265","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/J.1745-7254.2006.00255.X","volume":"27","author":"R Wang","year":"2006","unstructured":"Wang R, Yan H, Tang XC (2006) Progress in studies of huperzine A, a natural cholinesterase inhibitor from Chinese herbal medicine1. Acta Pharmacol Sin 27:1\u201326. https:\/\/doi.org\/10.1111\/J.1745-7254.2006.00255.X","journal-title":"Acta Pharmacol Sin"},{"key":"3604_CR266","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1351\/PAC200779040469\/MACHINEREADABLECITATION\/RIS","volume":"79","author":"D Bai","year":"2007","unstructured":"Bai D (2007) Development of huperzine A and B for treatment of Alzheimer\u2019s disease. Pure Appl Chem 79:469\u2013479. https:\/\/doi.org\/10.1351\/PAC200779040469\/MACHINEREADABLECITATION\/RIS","journal-title":"Pure Appl Chem"},{"key":"3604_CR267","doi-asserted-by":"publisher","unstructured":"Yang G, Wang Y, Tian J, Liu JP (2013) Huperzine A for Alzheimer\u2019s disease: a systematic review and meta-analysis of randomized clinical trials. PLoS One 8. https:\/\/doi.org\/10.1371\/JOURNAL.PONE.0074916","DOI":"10.1371\/JOURNAL.PONE.0074916"},{"key":"3604_CR268","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD007365.PUB2","author":"Z Hao","year":"2009","unstructured":"Hao Z, Liu M, Liu Z, Lv DH (2009) Huperzine A for vascular dementia. Cochrane database Syst Rev. https:\/\/doi.org\/10.1002\/14651858.CD007365.PUB2","journal-title":"Cochrane database Syst Rev"},{"key":"3604_CR269","doi-asserted-by":"publisher","unstructured":"Peavy GM, Jacobson MW, Goldstein JL et al (2010) Cognitive and functional decline in Huntington\u2019s disease: dementia criteria revisited. Mov Disord 25:1163. https:\/\/doi.org\/10.1002\/MDS.22953","DOI":"10.1002\/MDS.22953"},{"key":"3604_CR270","doi-asserted-by":"publisher","first-page":"62","DOI":"10.5498\/WJP.V3.I3.62","volume":"3","author":"Jj Vattakatuchery","year":"2013","unstructured":"Vattakatuchery Jj, Kurien R (2013) Acetylcholinesterase inhibitors in cognitive impairment in Huntington\u2019s disease: a brief review. World J psychiatry 3:62. https:\/\/doi.org\/10.5498\/WJP.V3.I3.62","journal-title":"World J psychiatry"},{"key":"3604_CR271","unstructured":". Farnsworth NR: The pharmacognosy of the periwinkles:... - Google Scholar. https:\/\/scholar.google.com\/scholar?hl=en&as_sdt=0%2C5&q=.+Farnsworth+NR%3A+The+pharmacognosy+of+the+periwinkles%3A+Vinca+and+Catharanthus.+Lloydia.1961%3B+24+%283%29%3A+105-138.+&btnG=. Accessed 29 Jun 2022"},{"key":"3604_CR272","doi-asserted-by":"publisher","unstructured":"Venkatesan R, Ji E, Kim SY (2015) Phytochemicals that regulate neurodegenerative disease by targeting neurotrophins: a comprehensive review. Biomed Res Int 2015. https:\/\/doi.org\/10.1155\/2015\/814068","DOI":"10.1155\/2015\/814068"},{"key":"3604_CR273","doi-asserted-by":"publisher","unstructured":"Varma S, Karwe MV, Lee T-C (2010) Effect of high hydrostatic pressure processing on lycopene isomers. Int J Food Eng 6. https:\/\/doi.org\/10.2202\/1556-3758.1752","DOI":"10.2202\/1556-3758.1752"},{"key":"3604_CR274","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1016\/S0308-8146(96)00177-X","volume":"59","author":"J Schierle","year":"1997","unstructured":"Schierle J, Bretzel W, B\u00fchler I et al (1997) Content and isomeric ratio of lycopene in food and human blood plasma. Food Chem 59:459\u2013465. https:\/\/doi.org\/10.1016\/S0308-8146(96)00177-X","journal-title":"Food Chem"},{"key":"3604_CR275","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1111\/J.1541-4337.2008.00044.X","volume":"7","author":"P Singh","year":"2008","unstructured":"Singh P, Goyal GK (2008) Dietary lycopene: its properties and anticarcinogenic effects. Compr Rev food Sci food Saf 7:255\u2013270. https:\/\/doi.org\/10.1111\/J.1541-4337.2008.00044.X","journal-title":"Compr Rev food Sci food Saf"},{"key":"3604_CR276","doi-asserted-by":"publisher","first-page":"186","DOI":"10.5455\/JICE.20140903012921","volume":"3","author":"D Jain","year":"2014","unstructured":"Jain D, Gangshettiwar A (2014) Combination of lycopene, quercetin and poloxamer 188 alleviates anxiety and depression in 3-nitropropionic acid-induced Huntington\u2019s disease in rats. J Intercult Ethnopharmacol 3:186. https:\/\/doi.org\/10.5455\/JICE.20140903012921","journal-title":"J Intercult Ethnopharmacol"},{"key":"3604_CR277","doi-asserted-by":"publisher","first-page":"50","DOI":"10.5606\/jebms.2021.75638","volume":"2","author":"K Erbakan","year":"2021","unstructured":"Erbakan K, Do\u011fano\u011flu A, Erba\u015f O (2021) Effects of lycopene on neurodegenerative diseases. J Exp Basic Med Sci 2:50\u201361. https:\/\/doi.org\/10.5606\/jebms.2021.75638","journal-title":"J Exp Basic Med Sci"},{"key":"3604_CR278","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1016\/J.BIOPHA.2018.12.151","volume":"111","author":"D Chen","year":"2019","unstructured":"Chen D, Huang C, Chen Z (2019) A review for the pharmacological effect of lycopene in central nervous system disorders. Biomed Pharmacother 111:791\u2013801. https:\/\/doi.org\/10.1016\/J.BIOPHA.2018.12.151","journal-title":"Biomed Pharmacother"},{"key":"3604_CR279","doi-asserted-by":"publisher","first-page":"S186","DOI":"10.1016\/J.JALZ.2010.05.591","volume":"6","author":"P Kumar","year":"2010","unstructured":"Kumar P, Kalonia H, Kumar A (2010) P1\u2013044: Protective effect of lycopene against 3-nitropropionic acid-induced Huntington\u2019s-like symptoms in rats. Alzheimer\u2019s Dement 6:S186\u2013S186. https:\/\/doi.org\/10.1016\/J.JALZ.2010.05.591","journal-title":"Alzheimer\u2019s Dement"},{"key":"3604_CR280","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1016\/J.LFS.2009.10.001","volume":"85","author":"P Kumar","year":"2009","unstructured":"Kumar P, Kalonia H, Kumar A (2009) Lycopene modulates nitric oxide pathways against 3-nitropropionic acid-induced neurotoxicity. Life Sci 85:711\u2013718. https:\/\/doi.org\/10.1016\/J.LFS.2009.10.001","journal-title":"Life Sci"},{"key":"3604_CR281","doi-asserted-by":"publisher","unstructured":"Sandhir R, Mehrotra A, Kamboj SS (2010) Lycopene prevents 3-nitropropionic acid-induced mitochondrial oxidative stress and dysfunctions in nervous system. 57:579\u2013587. https:\/\/doi.org\/10.1016\/J.NEUINT.2010.07.005","DOI":"10.1016\/J.NEUINT.2010.07.005"},{"key":"3604_CR282","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/J.NEURON.2005.06.005","volume":"47","author":"BB Il","year":"2005","unstructured":"Il BB, Xu H, Igarashi S et al (2005) p53 mediates cellular dysfunction and behavioral abnormalities in Huntington\u2019s disease. Neuron 47:29\u201341. https:\/\/doi.org\/10.1016\/J.NEURON.2005.06.005","journal-title":"Neuron"},{"issue":"4","key":"3604_CR283","doi-asserted-by":"publisher","first-page":"2619","DOI":"10.1007\/S12035-015-9230-2","volume":"53","author":"M Jang","year":"2015","unstructured":"Jang M, Cho IH (2015) Sulforaphane ameliorates 3-nitropropionic acid-induced striatal toxicity by activating the Keap1-Nrf2-ARE pathway and inhibiting the MAPKs and NF-\u03baB pathways. Mol Neurobiol 53(4):2619\u20132635. https:\/\/doi.org\/10.1007\/S12035-015-9230-2","journal-title":"Mol Neurobiol"},{"key":"3604_CR284","doi-asserted-by":"publisher","unstructured":"Manzoor MF, Ahmad N (2000) Food based phytochemical luteolin their derivatives, sources and medicinal benefits. https:\/\/doi.org\/10.22573\/spg.ijals.017.s12200084","DOI":"10.22573\/spg.ijals.017.s12200084"},{"key":"3604_CR285","doi-asserted-by":"publisher","unstructured":"Manzoor MF, Ahmad N, Ahmed Z et al (2019) Novel extraction techniques and pharmaceutical activities of luteolin and its derivatives. J Food Biochem 43. https:\/\/doi.org\/10.1111\/JFBC.12974","DOI":"10.1111\/JFBC.12974"},{"key":"3604_CR286","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/J.NEULET.2017.02.004","volume":"642","author":"W Hu","year":"2017","unstructured":"Hu W, Wang H, Liu Z et al (2017) Neuroprotective effects of lycopene in spinal cord injury in rats via antioxidative and anti-apoptotic pathway. Neurosci Lett 642:107\u2013112. https:\/\/doi.org\/10.1016\/J.NEULET.2017.02.004","journal-title":"Neurosci Lett"},{"key":"3604_CR287","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1111\/J.1742-7843.2006.PTO_300.X","volume":"98","author":"G Michels","year":"2006","unstructured":"Michels G, Mohamed GA, Weber N et al (2006) Effects of methylated derivatives of Luteolin isolated from Cyperus alopecuroides in rat H4IIE hepatoma cells*. Basic Clin Pharmacol Toxicol 98:168\u2013172. https:\/\/doi.org\/10.1111\/J.1742-7843.2006.PTO_300.X","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"3604_CR288","doi-asserted-by":"publisher","first-page":"2628","DOI":"10.3390\/MOLECULES13102628","volume":"13","author":"G Seelinger","year":"2008","unstructured":"Seelinger G, Merfort I, W\u00f6lfle U, Schempp CM (2008) Anti-carcinogenic effects of the flavonoid luteolin. Molecules 13:2628\u20132651. https:\/\/doi.org\/10.3390\/MOLECULES13102628","journal-title":"Molecules"},{"key":"3604_CR289","doi-asserted-by":"publisher","unstructured":"Cheng HY, Hsieh MT, Tsai FS et al (2010) Neuroprotective effect of luteolin on amyloid beta protein (25\u201335)-induced toxicity in cultured rat cortical neurons. Phytother Res 24 Suppl 1: https:\/\/doi.org\/10.1002\/PTR.2940","DOI":"10.1002\/PTR.2940"},{"key":"3604_CR290","doi-asserted-by":"publisher","first-page":"45","DOI":"10.4068\/CMJ.2014.50.2.45","volume":"50","author":"S-M Choi","year":"2014","unstructured":"Choi S-M, Kim BC, Cho Y-H et al (2014) Effects of flavonoid compounds on \u03b2-amyloid-peptide-induced neuronal death in cultured mouse cortical neurons. Chonnam Med J 50:45. https:\/\/doi.org\/10.4068\/CMJ.2014.50.2.45","journal-title":"Chonnam Med J"},{"key":"3604_CR291","doi-asserted-by":"publisher","unstructured":"Oliveira AM, Cardoso SM, Ribeiro M, et al (2015) Protective effects of 3-alkyl luteolin derivatives are mediated by Nrf2 transcriptional activity and decreased oxidative stress in Huntington\u2019s disease mouse striatal cells. 91:1\u201312. https:\/\/doi.org\/10.1016\/J.NEUINT.2015.10.004","DOI":"10.1016\/J.NEUINT.2015.10.004"},{"key":"3604_CR292","doi-asserted-by":"publisher","first-page":"2000146","DOI":"10.1002\/ARDP.202000146","volume":"353","author":"BVF Riccio","year":"2020","unstructured":"Riccio BVF, Sp\u00f3sito L, Carvalho GC et al (2020) Resveratrol isoforms and conjugates: a review from biosynthesis in plants to elimination from the human body. Arch Pharm (Weinheim) 353:2000146. https:\/\/doi.org\/10.1002\/ARDP.202000146","journal-title":"Arch Pharm (Weinheim)"},{"key":"3604_CR293","doi-asserted-by":"publisher","first-page":"38","DOI":"10.2991\/EFOOD.K.200203.001","volume":"1","author":"H Khan","year":"2020","unstructured":"Khan H, Ullah H, Tundis R et al (2020) Dietary flavonoids in the management of Huntington\u2019s disease: mechanism and clinical perspective. eFood 1:38\u201352. https:\/\/doi.org\/10.2991\/EFOOD.K.200203.001","journal-title":"eFood"},{"key":"3604_CR294","doi-asserted-by":"publisher","first-page":"100148","DOI":"10.1016\/J.COMTOX.2020.100148","volume":"17","author":"Y Hasan Siddique","year":"2021","unstructured":"Hasan Siddique Y, Rahul, Varshney H et al (2021) Effect of luteolin on the transgenic Drosophila model of Huntington\u2019s disease. Comput Toxicol 17:100148. https:\/\/doi.org\/10.1016\/J.COMTOX.2020.100148","journal-title":"Comput Toxicol"},{"key":"3604_CR295","doi-asserted-by":"publisher","first-page":"97","DOI":"10.4236\/OJMC.2015.54006","volume":"05","author":"Y Liu","year":"2015","unstructured":"Liu Y, Liu Y, Chen H et al (2015) Synthetic resveratrol derivatives and their biological activities: a review. Open J Med Chem 05:97\u2013105. https:\/\/doi.org\/10.4236\/OJMC.2015.54006","journal-title":"Open J Med Chem"},{"key":"3604_CR296","doi-asserted-by":"publisher","unstructured":"Berman AY, Motechin RA, Wiesenfeld MY, Holz MK (2017) The therapeutic potential of resveratrol: a review of clinical trials. NPJ Precis Oncol 1. https:\/\/doi.org\/10.1038\/S41698-017-0038-6","DOI":"10.1038\/S41698-017-0038-6"},{"key":"3604_CR297","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1021\/JF9504576","volume":"44","author":"BC Trela","year":"1996","unstructured":"Trela BC, Waterhouse AL (1996) Resveratrol: isomeric molar absorptivities and stability. J Agric Food Chem 44:1253\u20131257. https:\/\/doi.org\/10.1021\/JF9504576","journal-title":"J Agric Food Chem"},{"key":"3604_CR298","doi-asserted-by":"publisher","unstructured":"Gambini J, Ingl\u00e9s M, Olaso G et al (2015) Properties of resveratrol: in vitro and in vivo studies about metabolism, bioavailability, and biological effects in animal models and humans. Oxid Med Cell Longev 2015. https:\/\/doi.org\/10.1155\/2015\/837042","DOI":"10.1155\/2015\/837042"},{"key":"3604_CR299","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/J.MEDICI.2016.03.003","volume":"52","author":"L Kur\u0161vietien\u0117","year":"2016","unstructured":"Kur\u0161vietien\u0117 L, Stanevi\u010dien\u0117 I, Mongirdien\u0117 A, Bernatonien\u0117 J (2016) Multiplicity of effects and health benefits of resveratrol. Medicina (Kaunas) 52:148\u2013155. https:\/\/doi.org\/10.1016\/J.MEDICI.2016.03.003","journal-title":"Medicina (Kaunas)"},{"key":"3604_CR300","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/J.EXPNEUROL.2011.08.014","volume":"232","author":"GM Pasinetti","year":"2011","unstructured":"Pasinetti GM, Wang J, Marambaud P et al (2011) Neuroprotective and metabolic effects of resveratrol: therapeutic implications for Huntington\u2019s disease and other neurodegenerative disorders. Exp Neurol 232:1\u20136. https:\/\/doi.org\/10.1016\/J.EXPNEUROL.2011.08.014","journal-title":"Exp Neurol"},{"key":"3604_CR301","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1038\/NG1534","volume":"37","author":"JA Parker","year":"2005","unstructured":"Parker JA, Arango M, Abderrahmane S et al (2005) Resveratrol rescues mutant polyglutamine cytotoxicity in nematode and mammalian neurons. Nat Genet 37:349\u2013350. https:\/\/doi.org\/10.1038\/NG1534","journal-title":"Nat Genet"},{"key":"3604_CR302","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1093\/HMG\/DDQ460","volume":"20","author":"P Maher","year":"2011","unstructured":"Maher P, Dargusch R, Bodai L et al (2011) ERK activation by the polyphenols fisetin and resveratrol provides neuroprotection in multiple models of Huntington\u2019s disease. Hum Mol Genet 20:261\u2013270. https:\/\/doi.org\/10.1093\/HMG\/DDQ460","journal-title":"Hum Mol Genet"},{"key":"3604_CR303","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1016\/j.phytochem.2015.02.004","volume":"115","author":"AP Vale","year":"2015","unstructured":"Vale AP, Santos J, Brito NV et al (2015) Evaluating the impact of sprouting conditions on the glucosinolate content of Brassica oleracea sprouts. Phytochemistry 115:252\u2013260. https:\/\/doi.org\/10.1016\/j.phytochem.2015.02.004","journal-title":"Phytochemistry"},{"key":"3604_CR304","doi-asserted-by":"publisher","unstructured":"Fahey JW, Holtzclaw WD, Wehage SL, Wade KL, Stephenson KK, Talalay P (2015) Sulforaphane bioavailability from glucoraphanin-rich broccoli: control by active endogenous myrosinase. PLOS ONE 10:e0140963. https:\/\/doi.org\/10.1371\/journal.pone.0140963","DOI":"10.1371\/journal.pone.0140963"},{"key":"3604_CR305","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/J.EXPNEUROL.2010.05.006","volume":"225","author":"DJ Ho","year":"2010","unstructured":"Ho DJ, Calingasan NY, Wille E et al (2010) Resveratrol protects against peripheral deficits in a mouse model of Huntington\u2019s disease. Exp Neurol 225:74\u201384. https:\/\/doi.org\/10.1016\/J.EXPNEUROL.2010.05.006","journal-title":"Exp Neurol"},{"key":"3604_CR306","doi-asserted-by":"publisher","first-page":"10505","DOI":"10.1021\/JF801989E","volume":"56","author":"M Vermeulen","year":"2008","unstructured":"Vermeulen M, Kl\u00f6pping-Ketelaars IWAA, Van Den Berg R, Vaes WHJ (2008) Bioavailability and kinetics of sulforaphane in humans after consumption of cooked versus raw broccoli. J Agric Food Chem 56:10505\u201310509. https:\/\/doi.org\/10.1021\/JF801989E","journal-title":"J Agric Food Chem"},{"key":"3604_CR307","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/J.TIFS.2017.02.002","volume":"69","author":"AT Dinkova-Kostova","year":"2017","unstructured":"Dinkova-Kostova AT, Fahey JW, Kostov RV, Kensler TW (2017) KEAP1 and done? Targeting the NRF2 pathway with sulforaphane. Trends Food Sci Technol 69:257\u2013269. https:\/\/doi.org\/10.1016\/J.TIFS.2017.02.002","journal-title":"Trends Food Sci Technol"},{"issue":"Pt 1","key":"3604_CR308","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1016\/j.freeradbiomed.2022.10.001","volume":"193","author":"Q Li","year":"2022","unstructured":"Li Q, Fadoul G, Ikonomovic M, Yang T, Zhang F (2022) Sulforaphane promotes white matter plasticity and improves long-term neurological outcomes after ischemic stroke via the Nrf2 pathway. Free Radic Biol Med 193(Pt 1):292\u2013303. https:\/\/doi.org\/10.1016\/j.freeradbiomed.2022.10.001","journal-title":"Free Radic Biol Med"},{"key":"3604_CR309","doi-asserted-by":"publisher","unstructured":"Kim JK, Park SU (2016) Current potential health benefits of sulforaphane. EXCLI J 15:571\u2013577. https:\/\/doi.org\/10.17179\/EXCLI2016-485","DOI":"10.17179\/EXCLI2016-485"},{"key":"3604_CR310","doi-asserted-by":"publisher","unstructured":"Liu Y, Hettinger CL, Zhang D, Rezvani K, Wang X, Wang H (2014) Sulforaphane enhances proteasomal and autophagic activities in mice and is a potential therapeutic reagent for Huntington\u2019s disease. J Neurochem 129:539\u2013547. https:\/\/doi.org\/10.1111\/jnc.12647","DOI":"10.1111\/jnc.12647"},{"key":"3604_CR311","doi-asserted-by":"publisher","unstructured":"Subedi L, Cho K, Park YU et al (2019) Sulforaphane-enriched broccoli sprouts pretreated by pulsed electric fields reduces neuroinflammation and ameliorates scopolamine-induced amnesia in mouse brain through its antioxidant ability via Nrf2-HO-1 activation. Oxid Med Cell Longev 2019. https:\/\/doi.org\/10.1155\/2019\/3549274","DOI":"10.1155\/2019\/3549274"},{"issue":"2","key":"3604_CR312","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1007\/S12035-012-8329-Y","volume":"47","author":"A Ulusoy","year":"2012","unstructured":"Ulusoy A, Di Monte DA (2012) \u03b1-Synuclein elevation in human neurodegenerative diseases: experimental, pathogenetic, and therapeutic implications. Mol Neurobiol 47(2):484\u2013494. https:\/\/doi.org\/10.1007\/S12035-012-8329-Y","journal-title":"Mol Neurobiol"},{"issue":"7","key":"3604_CR313","doi-asserted-by":"publisher","first-page":"2965","DOI":"10.1007\/S00253-018-8814-Y","volume":"102","author":"X Cai","year":"2018","unstructured":"Cai X, Seitl I, Mu W et al (2018) Biotechnical production of trehalose through the trehalose synthase pathway: current status and future prospects. Appl Microbiol Biotechnol 102(7):2965\u20132976. https:\/\/doi.org\/10.1007\/S00253-018-8814-Y","journal-title":"Appl Microbiol Biotechnol"},{"key":"3604_CR314","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1038\/NM985","volume":"10","author":"M Tanaka","year":"2004","unstructured":"Tanaka M, Machida Y, Niu S et al (2004) Trehalose alleviates polyglutamine-mediated pathology in a mouse model of Huntington disease. Nat Med 10:148\u2013154. https:\/\/doi.org\/10.1038\/NM985","journal-title":"Nat Med"},{"key":"3604_CR315","doi-asserted-by":"publisher","first-page":"A94","DOI":"10.1136\/JNNP-2016-314597.267","volume":"87","author":"J Brokowska","year":"2016","unstructured":"Brokowska J, Ha\u0107 A, W\u0119grzyn G, Herman-Antosiewicz A (2016) L12 Sulforaphane reduces the level of exogenous mutated huntingtin protein in normal human fibroblasts. J Neurol Neurosurg Psychiatry 87:A94\u2013A94. https:\/\/doi.org\/10.1136\/JNNP-2016-314597.267","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"3604_CR316","doi-asserted-by":"publisher","unstructured":"Elbein AD, Pan YT, Pastuszak I, Carroll D (2003) New insights on trehalose: a multifunctional molecule. Glycobiology 13. https:\/\/doi.org\/10.1093\/GLYCOB\/CWG047","DOI":"10.1093\/GLYCOB\/CWG047"},{"key":"3604_CR317","doi-asserted-by":"publisher","first-page":"2020","DOI":"10.1002\/JPS.22458","volume":"100","author":"S Ohtake","year":"2011","unstructured":"Ohtake S, Wang YJ (2011) Trehalose: current use and future applications. J Pharm Sci 100:2020\u20132053. https:\/\/doi.org\/10.1002\/JPS.22458","journal-title":"J Pharm Sci"},{"key":"3604_CR318","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1111\/BPH.14623","volume":"176","author":"M Khalifeh","year":"2019","unstructured":"Khalifeh M, Barreto GE, Sahebkar A (2019) Trehalose as a promising therapeutic candidate for the treatment of Parkinson\u2019s disease. Br J Pharmacol 176:1173\u20131189. https:\/\/doi.org\/10.1111\/BPH.14623","journal-title":"Br J Pharmacol"},{"key":"3604_CR319","doi-asserted-by":"publisher","first-page":"e90202","DOI":"10.1371\/JOURNAL.PONE.0090202","volume":"9","author":"MA Fernandez-Estevez","year":"2014","unstructured":"Fernandez-Estevez MA, Casarejos MJ, Sendon JL et al (2014) Trehalose reverses cell malfunction in fibroblasts from normal and Huntington\u2019s disease patients caused by proteosome inhibition. PLoS One 9:e90202. https:\/\/doi.org\/10.1371\/JOURNAL.PONE.0090202","journal-title":"PLoS One"},{"key":"3604_CR320","doi-asserted-by":"publisher","first-page":"17121","DOI":"10.3390\/IJMS131217121","volume":"13","author":"A Sgarbossa","year":"2012","unstructured":"Sgarbossa A (2012) Natural biomolecules and protein aggregation: emerging strategies against amyloidogenesis. Int J Mol Sci 13:17121\u201317137. https:\/\/doi.org\/10.3390\/IJMS131217121","journal-title":"Int J Mol Sci"},{"key":"3604_CR321","doi-asserted-by":"publisher","first-page":"1443","DOI":"10.2147\/DDDT.S94666","volume":"10","author":"Y Zeng","year":"2016","unstructured":"Zeng Y, Guo W, Xu G et al (2016) Xyloketal-derived small molecules show protective effect by decreasing mutant Huntingtin protein aggregates in Caenorhabditis elegans model of Huntington\u2019s disease. Drug Des Devel Ther 10:1443\u20131451. https:\/\/doi.org\/10.2147\/DDDT.S94666","journal-title":"Drug Des Devel Ther"},{"key":"3604_CR322","doi-asserted-by":"publisher","first-page":"3496","DOI":"10.3390\/MOLECULES20033496","volume":"20","author":"VKW Wong","year":"2015","unstructured":"Wong VKW, Wu AG, Wang JR et al (2015) Neferine attenuates the protein level and toxicity of mutant huntingtin in PC-12 cells via induction of autophagy. Molecules 20:3496\u20133514. https:\/\/doi.org\/10.3390\/MOLECULES20033496","journal-title":"Molecules"},{"key":"3604_CR323","doi-asserted-by":"publisher","first-page":"22618","DOI":"10.3390\/IJMS141122618","volume":"14","author":"AG Wu","year":"2013","unstructured":"Wu AG, Wong VKW, Xu SW et al (2013) Onjisaponin B derived from Radix Polygalae enhances autophagy and accelerates the degradation of mutant \u03b1-synuclein and huntingtin in PC-12 cells. Int J Mol Sci 14:22618\u201322641. https:\/\/doi.org\/10.3390\/IJMS141122618","journal-title":"Int J Mol Sci"},{"key":"3604_CR324","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1111\/CBDD.12259","volume":"83","author":"GM Walter","year":"2014","unstructured":"Walter GM, Raveh A, Mok SA et al (2014) High-throughput screen of natural product extracts in a yeast model of polyglutamine proteotoxicity. Chem Biol Drug Des 83:440\u2013449. https:\/\/doi.org\/10.1111\/CBDD.12259","journal-title":"Chem Biol Drug Des"},{"key":"3604_CR325","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1002\/PTR.5246","volume":"29","author":"A Sun","year":"2015","unstructured":"Sun A, Xu X, Lin J et al (2015) Neuroprotection by saponins. Phytother Res 29:187\u2013200. https:\/\/doi.org\/10.1002\/PTR.5246","journal-title":"Phytother Res"},{"key":"3604_CR326","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1172\/JCI45364","volume":"121","author":"I Munoz-Sanjuan","year":"2011","unstructured":"Munoz-Sanjuan I, Bates GP (2011) The importance of integrating basic and clinical research toward the development of new therapies for Huntington disease. J Clin Invest 121:476\u2013483. https:\/\/doi.org\/10.1172\/JCI45364","journal-title":"J Clin Invest"},{"key":"3604_CR327","doi-asserted-by":"publisher","first-page":"2701","DOI":"10.2174\/138161206777698693","volume":"12","author":"R Bonelli","year":"2006","unstructured":"Bonelli R, Wenning G (2006) Pharmacological management of Huntington\u2019s disease: an evidence-based review. Curr Pharm Des 12:2701\u20132720. https:\/\/doi.org\/10.2174\/138161206777698693","journal-title":"Curr Pharm Des"},{"key":"3604_CR328","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1038\/NRD3160","volume":"9","author":"MM Braun","year":"2010","unstructured":"Braun MM, Farag-El-Massah S, Xu K, Cot\u00e9 TR (2010) Emergence of orphan drugs in the United States: a quantitative assessment of the first 25 years. Nat Rev Drug Discov 9:519\u2013522. https:\/\/doi.org\/10.1038\/NRD3160","journal-title":"Nat Rev Drug Discov"},{"key":"3604_CR329","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1038\/CLPT.2012.89","volume":"92","author":"J Woodcock","year":"2012","unstructured":"Woodcock J (2012) The future of orphan drug development. Clin Pharmacol Ther 92:146\u2013148. https:\/\/doi.org\/10.1038\/CLPT.2012.89","journal-title":"Clin Pharmacol Ther"},{"key":"3604_CR330","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/S1474-4422(14)70262-5","volume":"14","author":"D Angus","year":"2015","unstructured":"Angus D, Herd C, Stone C et al (2015) Safety, tolerability, and efficacy of PBT2 in Huntington\u2019s disease: a phase 2, randomised, double-blind, placebo-controlled trial. Lancet Neurol 14:39\u201347. https:\/\/doi.org\/10.1016\/S1474-4422(14)70262-5","journal-title":"Lancet Neurol"},{"key":"3604_CR331","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1016\/S1474-4422(11)70233-2","volume":"10","author":"JG De Yebenes","year":"2011","unstructured":"De Yebenes JG, Landwehrmeyer B, Squitieri F et al (2011) Pridopidine for the treatment of motor function in patients with Huntington\u2019s disease (MermaiHD): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet Neurol 10:1049\u20131057. https:\/\/doi.org\/10.1016\/S1474-4422(11)70233-2","journal-title":"Lancet Neurol"},{"key":"3604_CR332","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1002\/MDS.25362","volume":"28","author":"K Karl","year":"2013","unstructured":"Karl K, McGarry A, McDermott MP et al (2013) A randomized, double-blind, placebo-controlled trial of pridopidine in Huntington\u2019s disease. Mov Disord 28:1407\u20131415. https:\/\/doi.org\/10.1002\/MDS.25362","journal-title":"Mov Disord"},{"key":"3604_CR333","doi-asserted-by":"publisher","unstructured":"Levin SW, Baker EH, Zein WM, Zhang Z, Quezado ZMN, Miao N, Gropman A, Griffin KJ et al (2014) Oral cysteamine bitartrate and N-acetylcysteine for patients with infantile neuronal ceroid lipofuscinosis: a pilot study. Lancet Neurol 13:777\u2013787. https:\/\/doi.org\/10.1016\/s1474-4422(14)70142-5","DOI":"10.1016\/s1474-4422(14)70142-5"},{"key":"3604_CR334","doi-asserted-by":"publisher","unstructured":"Tabrizi SJ, Langbehn DR, Leavitt BR, Roos RA, Durr A, Craufurd D, Kennard C, Hicks SL et al (2009) Biological and clinical manifestations of Huntington\u2019s disease in the longitudinal TRACK-HD study: cross-sectional analysis of baseline data. The Lancet Neurology 8:791\u2013801. https:\/\/doi.org\/10.1016\/s1474-4422(09)70170-x","DOI":"10.1016\/s1474-4422(09)70170-x"},{"key":"3604_CR335","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1212\/WNL.0000000000004209","volume":"89","author":"SM Hersch","year":"2017","unstructured":"Hersch SM, Schifitto G, Oakes D et al (2017) The CREST-E study of creatine for Huntington disease: a randomized controlled trial. Neurology 89:594\u2013601. https:\/\/doi.org\/10.1212\/WNL.0000000000004209","journal-title":"Neurology"},{"key":"3604_CR336","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1002\/MDC3.12483","volume":"4","author":"FB Rodrigues","year":"2017","unstructured":"Rodrigues FB, Duarte GS, Costa J et al (2017) Tetrabenazine versus deutetrabenazine for Huntington\u2019s disease: twins or distant cousins? Mov Disord Clin Pract 4:582\u2013585. https:\/\/doi.org\/10.1002\/MDC3.12483","journal-title":"Mov Disord Clin Pract"},{"key":"3604_CR337","doi-asserted-by":"publisher","unstructured":"Claassen DO, Carroll B, De Boer LM, Wu E, Ayyagari R, Gandhi S, Stamler D (2017) Indirect tolerability comparison of Deutetrabenazine and Tetrabenazine for Huntington disease. J Clin Mov Disord 41(4):1\u201311. https:\/\/doi.org\/10.1186\/S40734-017-0051-5","DOI":"10.1186\/S40734-017-0051-5"},{"key":"3604_CR338","doi-asserted-by":"publisher","unstructured":"Rodrigues FB, Duarte GS, Costa J, Ferreira JJ, Wild JJ (2017) Meta-research metrics matter: letter regarding article \u201cindirect tolerability comparison of Deutetrabenazine and Tetrabenazine for Huntington disease.\u201d J Clin Mov Disord 41(4):1\u20133. https:\/\/doi.org\/10.1186\/S40734-017-0067-X","DOI":"10.1186\/S40734-017-0067-X"},{"key":"3604_CR339","doi-asserted-by":"publisher","first-page":"81","DOI":"10.4103\/0973-7847.120505","volume":"7","author":"S Choudhary","year":"2013","unstructured":"Choudhary S, Kumar P, Malik J (2013) Plants and phytochemicals for Huntington\u2019s disease. Pharmacogn Rev 7:81\u201391. https:\/\/doi.org\/10.4103\/0973-7847.120505","journal-title":"Pharmacogn Rev"}],"container-title":["Molecular Neurobiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12035-023-03604-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12035-023-03604-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12035-023-03604-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,29]],"date-time":"2024-02-29T22:22:56Z","timestamp":1709245376000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12035-023-03604-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,12]]},"references-count":339,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,3]]}},"alternative-id":["3604"],"URL":"https:\/\/doi.org\/10.1007\/s12035-023-03604-4","relation":{},"ISSN":["0893-7648","1559-1182"],"issn-type":[{"value":"0893-7648","type":"print"},{"value":"1559-1182","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,12]]},"assertion":[{"value":"7 June 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 August 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 September 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interest"}}]}}